var title_f7_57_8080="Varicocele";
var content_f7_57_8080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varicocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 341px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A varicocele is a collection of dilated and tortuous veins in the pampiniform plexus surrounding the spermatic cord. On physical examination, the spermatic cord has a \"bag of worms\" appearance that increases with standing or the valsalva maneuver.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8080=[""].join("\n");
var outline_f7_57_8080=null;
var title_f7_57_8081="Auricle anatomy";
var content_f7_57_8081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auricle anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    External ear. Auricle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Atlas of Human Anatomy. Copyright &copy; 2008 Anatomical Chart Co.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8081=[""].join("\n");
var outline_f7_57_8081=null;
var title_f7_57_8082="Patient information: Poliomyelitis (The Basics)";
var content_f7_57_8082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/4/23619\">",
"         Patient information: Vaccines for adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/22/28003\">",
"         Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/44/21187\">",
"         Patient information: Vaccines for travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/42/18084\">",
"         Patient information: Why does my child need vaccines? (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Poliomyelitis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/poliomyelitis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8415303\">",
"      <span class=\"h1\">",
"       What is poliomyelitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Poliomyelitis (commonly called &ldquo;polio&rdquo;) is an infection caused by a virus called &ldquo;poliovirus.&rdquo; Most people who get polio have no symptoms. But in rare cases, polio can cause a person&rsquo;s muscles to stop working (called &ldquo;paralysis&rdquo;) or death. &nbsp;",
"     </p>",
"     <p>",
"      Polio used to be common in the US. But no cases have been reported in the US for more than 30 years. In the mid 1950s, doctors started giving a vaccine to prevent polio. It is one of the vaccines doctors recommend for all babies.",
"     </p>",
"     <p>",
"      Polio is a still a problem in parts of Asia and Africa. People who travel from those areas to the US might have the virus and could spread it to people who have not had the vaccine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8415318\">",
"      <span class=\"h1\">",
"       What are the symptoms of polio?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with polio have no symptoms. A small number of people get symptoms that can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Headache",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Feeling sick to your stomach (nausea) and throwing up (vomiting)",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      A very small number of people who have those symptoms also get more serious symptoms. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Very bad pain in the neck, back, and muscles",
"       </li>",
"       <li>",
"        Weakness or paralysis in certain muscles &ndash; This can affect the muscles of the legs, arms, and the muscles that help you breathe.",
"       </li>",
"       <li>",
"        Problems swallowing and speaking",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who survive these symptoms can get a condition called &ldquo;post-polio syndrome.&rdquo; It happens many years after the infection. Symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Weak, shrunken muscles",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Trouble walking &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8415333\">",
"      <span class=\"h1\">",
"       How does polio spread?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Poliovirus is most commonly spread by contact with the bowel movements (called &ldquo;feces&rdquo;) of a person infected with poliovirus. This can happen different ways, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Eating foods or drinking liquids that have poliovirus in them &ndash; This can happen if the food or water comes in contact with sewage water.",
"       </li>",
"       <li>",
"        Touching surfaces or things that have feces from a person with the virus on them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Poliovirus can also be spread through saliva (also known as &ldquo;spit&rdquo;). That means people can also get polio by sharing food or utensils with an infected person.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8415350\">",
"      <span class=\"h1\">",
"       Is there a test for polio?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The main test for polio involves lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;). During this procedure, a doctor puts a thin needle into the lower back and removes a small amount of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. Another doctor then does lab tests on the spinal fluid to check for poliovirus.",
"     </p>",
"     <p>",
"      <strong>",
"       How is polio treated?",
"      </strong>",
"      &ndash; Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Medicines to ease pain",
"       </li>",
"       <li>",
"        Physical therapy",
"       </li>",
"       <li>",
"        Mechanical ventilation &ndash; This involves using a machine that helps with breathing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8415365\">",
"      <span class=\"h1\">",
"       Can polio be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Getting the polio vaccine can prevent polio. This vaccine is given to babies in a series of 4 shots between the ages of 2 months and 6 years.",
"     </p>",
"     <p>",
"      Most adults living in the US today got the vaccine during childhood. But adults who are traveling to countries where polio is still a problem should get a second series of the vaccine (called a polio &ldquo;booster&rdquo;) for extra protection. The Centers for Disease Prevention and Control (CDC) updates a list of these countries at this website:",
"      <a class=\"external\" href=\"file://wwwnc.cdc.gov/travel/notices/in-the-news/polio-outbreaks.htm\">",
"       wwwnc.cdc.gov/travel/notices/in-the-news/polio-outbreaks.htm",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8415380\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=see_link\">",
"       Patient information: Vaccines for travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=see_link\">",
"       Patient information: Why does my child need vaccines? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       Patient information: Vaccines for adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=see_link\">",
"       Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/57/8082?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83751 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-33CB703E27-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8082=[""].join("\n");
var outline_f7_57_8082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415303\">",
"      What is poliomyelitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415318\">",
"      What are the symptoms of polio?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415333\">",
"      How does polio spread?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415350\">",
"      Is there a test for polio?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415365\">",
"      Can polio be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8415380\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/22/28003?source=related_link\">",
"      Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/44/21187?source=related_link\">",
"      Patient information: Vaccines for travel (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/42/18084?source=related_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8083="Cantharidin: Drug information";
var content_f7_57_8083=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cantharidin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/44/8899?source=see_link\">",
"    see \"Cantharidin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Canthacur&reg;;",
"     </li>",
"     <li>",
"      Cantharone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Common or periungual warts:",
"     </b>",
"     Topical: Apply to lesion and to 1-3 mm surrounding margin; once dry, cover with nonporous tape; remove tape in 24 hours. Treat once weekly for new or resistant lesions (2-3 treatments may be necessary). Patients scheduled for curettage should return 24 hours after treatment for procedure; reassess in 4 weeks for resolution and/or healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Molluscum contagiosum:",
"     </b>",
"     Topical: Apply directly to lesion; once dry, cover large or resistant lesions with nonporous tape for 4-6 hours (Cantharone&reg;) or 6-8 hours (Canthacur&reg;). May retreat once weekly for new or resistant lesions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Palpebral warts:",
"     </b>",
"     Topical: Canthacur&reg;: Apply directly to lesion and leave uncovered. Avoid touching normal skin or applying inside eyelash; may repeat in 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plantar warts:",
"     </b>",
"     Topical: Apply to lesion and to 1-3 mm surrounding margin; once dry, cover with nonporous tape for up to 1 week; may retreat in 1-2 weeks if necessary",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;3 years and Adolescents: Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Canthacur&reg; product insert does not specify minimum age requirement for use in children.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15794328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15794329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F15827785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canthacur&reg;: Cantharidin 0.7% in a film-forming vehicle (7.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cantharone&reg;: Cantharidin 0.7% in a film-forming vehicle (7.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15827784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15827780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; apply to clean skin. No cutting or prior treatment is required. Occasionally, nails must be trimmed to expose subungual warts to medication. Using a wooden applicator stick, apply to lesion(s). Allow to dry for a few minutes. Palpebral warts treated with Canthacur&reg; should be left uncovered. Avoid touching normal skin or applying inside eyelash; instruct patients not to touch eyelid. Large or resistant lesions due to molluscum contagiosum should be covered with a piece of nonporous adhesive tape for 4-6 hours (Cantharone&reg;) or 6-8 hours (Canthacur&reg;). Other lesions should be covered with a piece of nonporous adhesive tape for 4-6 hours for up to 1 week. Within 24 hours, a blister forms and healing is typically evident within 7 days. Additional treatment may be necessary for resistant lesions. Medication may be used for pain and itching at night.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Removal of common warts, molluscum contagiosum, and periungual warts",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Annular warts, depigmentation (temporary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Blisters, burning, pain, tenderness, tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Chemical lymphangitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canthacur&reg;: Hypersensitivity to cantharidin or any component of the formulation; alcoholic beverages for several hours after treatment; use on mosaic warts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cantharone&reg;: Use in diabetics or in individuals with impaired peripheral circulation; use near eyes or on face or mucous membranes; in anogenital, intertriginous, or axilla areas",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15827760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic: Strong vesicant that may cause blistering of normal skin or mucous membranes; reactions may be more severe in patients with fair complexion and/or blue eyes. Do not apply to irritated or inflamed skin. Residual pigmentation has been reported (rarely) with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate personnel: Should be applied only by a physician; not recommended for dispensing to patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use:",
"     <b>",
"      For external use only.",
"     </b>",
"     Not for use near the eyes, on mucous membranes, in anogenital, intertriginous or axilla areas. Avoid treating multiple lesions during the first visit to determine patient tolerability. Delay retreatment if area is inflamed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15827758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is not recommended during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15827759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15827783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treated areas for adequate healing; pain and tolerability of treatment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Canthacur (CA);",
"     </li>",
"     <li>",
"      Cantharone (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15827764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cantharidin is a vesicant thought to cause wart exfoliation via its acantholytic actions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8838 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8083=[""].join("\n");
var outline_f7_57_8083=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145087\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145095\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145088\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145092\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145089\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794328\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794329\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827785\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145073\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827784\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827780\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145082\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145093\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145084\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827760\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298953\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218857\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827758\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827759\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827783\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145085\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827764\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/44/8899?source=related_link\">",
"      Cantharidin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8084="Enflurane: Patient drug information";
var content_f7_57_8084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enflurane: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=see_link\">",
"     see \"Enflurane: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Compound 347&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put you to sleep for surgery.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enflurane or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703757",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or a family member have had malignant hyperthermia after getting an anesthetic. Signs of this health problem include a very high fever, a fast heartbeat, muscle stiffness, and trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may not be alert. Avoid driving and doing other tasks or actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698063",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Good mouth care may help. Ask the doctor for a drug to help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698330",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shivering.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698973",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a liquid for breathing into the lungs by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11486 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A20BFA4EA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8084=[""].join("\n");
var outline_f7_57_8084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021883\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021885\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021884\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021888\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021889\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021891\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021887\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021892\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021893\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/47/34548?source=related_link\">",
"      Enflurane: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8085="Artemether and lumefantrine: Patient drug information";
var content_f7_57_8085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Artemether and lumefantrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=see_link\">",
"     see \"Artemether and lumefantrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/30/15846?source=see_link\">",
"     see \"Artemether and lumefantrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7695214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coartem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691950",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to artemether, lumefantrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat or are taking drugs to control the heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low magnesium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush tablet and mix with 1 or 2 teaspoons (5 or 10 mL) of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up within 1 hour of taking this drug, take 1 more dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you throw up again after taking the second dose, call your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10843 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8085=[""].join("\n");
var outline_f7_57_8085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695214\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021213\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021215\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021214\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021219\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021220\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021222\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021217\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021218\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021223\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021224\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/58/37798?source=related_link\">",
"      Artemether and lumefantrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/30/15846?source=related_link\">",
"      Artemether and lumefantrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8086="Neurochemical targets";
var content_f7_57_8086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Medications that improve narcolepsy target specific neurochemical systems",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 407px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Narcolepsy is caused by a loss of the orexin-producing neurons in the lateral hypothalamus. Normally, the orexin neuropeptides excite neurons that promote wakefulness and suppress REM sleep including monoaminergic areas such as the locus coeruleus, raphe nuclei, ventral tegmental area, periaqueductal grey, and tuberomammillary nucleus as well as cholinergic areas such as the basal forebrain and pedunculopontine and laterodorsal tegmental nuclei (PPT/LDT). Most medications that improve sleepiness do so by enhancing dopamine signaling, and most cataplexy-suppressing medications increase norepinephrine and/or serotonin signaling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8086=[""].join("\n");
var outline_f7_57_8086=null;
var title_f7_57_8087="Complex complicated cysts";
var content_f7_57_8087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F80160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F80160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Ultrasound appearance of complex and complicated cysts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Complex cyst with nodule. B) Complex cyst. C) Cyst with thin septa and nodular portion. D) Complicated cyst with \"swirling\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8087=[""].join("\n");
var outline_f7_57_8087=null;
var title_f7_57_8088="Diffuse esophageal spasm HREPT and manometry";
var content_f7_57_8088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High-resolution esophageal pressure topography and conventional manometry in a patient with diffuse esophageal spasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 545px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution esophageal pressure topography (panel A) and standard manometry (panel B) from a patient with diffuse esophageal spasm. High-resolution esophageal pressure topography reveals simultaneous contractions in the distal esophagus (orange and red bars to the right of the thick arrow) with normal relaxation of the lower esophageal sphincter (thin arrow). There is abnormal bolus transit shown by impedance recording at the top of both panel A and panel B. Notice the subsequent normally progressing peristaltic wave (to the right of the thin arrow). The corresponding findings on conventional manometry are seen in the tracing on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8088=[""].join("\n");
var outline_f7_57_8088=null;
var title_f7_57_8089="Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage";
var content_f7_57_8089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Eelco FM Wijdicks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8089/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/57/8089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapies are widely employed in clinical medicine based upon randomized trials that have rigorously defined their benefits relative to associated bleeding risks. Patients with acute or prior intracerebral hemorrhage (ICH) have generally been excluded from antithrombotic trials because of fears of worsening CNS bleeding. Consequently, the efficacy and safety of antithrombotic agents in patients with acute or prior ICH are derived mainly from weaker observational data. This topic review discusses anticoagulant and antiplatelet therapy for the prevention or treatment of venous thromboembolism in patients with an acute ICH and the risk of long term antithrombotic therapies in ICH survivors.",
"   </p>",
"   <p>",
"    The overall risk, diagnosis, and treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated ICH are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE ICH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one stroke in 10 is due to primary ICH; an even higher fraction of strokes are ICHs in Mexican-Americans and Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Common causes include hypertension and cerebral amyloid angiopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/1\">",
"     1",
"    </a>",
"    ]. These strokes are particularly lethal and devastating, with a 40 percent mortality at one month and with only about one-half of survivors being able to live independently [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. However, the range of stroke severity is wide; some ICHs cause mild neurologic deficits and are clinically indistinguishable from small \"lacunar\" infarcts; brain imaging with computed tomography or magnetic resonance imaging is required in order to reliably diagnose ICH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=see_link\">",
"     \"Cerebral amyloid angiopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antithrombotic agents in patients with an acute ICH for prevention or treatment of deep vein thrombosis and pulmonary emboli prompts concern about hematoma expansion with attendant neurologic deterioration. There is a paucity of high-quality studies to guide management [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/4\">",
"     4",
"    </a>",
"    ]; the available information is summarized in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recurrent bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Active bleeding into the brain is usually confined to the first six hours following spontaneous ICH, with 10 to 15 percent of patients showing hematoma enlargement between 6 and 24 hours from the onset of ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Ongoing or recurrent bleeding is infrequent after 24 hours, but has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The precise frequency of recurrent bleeding is not certain, but enlargement of ICH between 24 hours and two weeks occurs in less than 5 percent, and probably closer to 1 to 2 percent, of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. No consistent predictors of hematoma expansion after the first six hours have been identified, with the exception of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Rate of recurrence'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Clinical presentation and diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Venous thromboembolism in acute ICH patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically evident deep vein thrombosis is typically delayed for more than one week after stroke, and has been reported in 2 to 15 percent of patients with ICH (",
"    <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"     table 1",
"    </a>",
"    ). The incidence of",
"    <strong>",
"     asymptomatic",
"    </strong>",
"    VTE is substantially higher. Studies employing ultrasonography have reported frequencies of occult VTE in acute ICH patients with hemiplegia as high as 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/11\">",
"     11",
"    </a>",
"    ]. Pulmonary embolus (PE), often unassociated with clinically recognized VTE, usually occurs two to four weeks after onset of acute ICH in about 1 to 5 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"     table 1",
"    </a>",
"    ). Stroke severity (and particularly leg weakness) is a strong predictor of VTE in acute ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/11\">",
"     11",
"    </a>",
"    ]. In one study, African-Americans with acute ICH had a higher rate of VTE after adjustment for other predictors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/12\">",
"     12",
"    </a>",
"    ], and in a Japanese study, female sex was a strong (sixfold) independent predictor of asymptomatic VTE detected by ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because ICH often causes severe leg weakness and immobility, the risk of VTE is increased. It may be more frequent in ICH patients than in those with acute ischemic stroke as a result of withholding subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, estimates of the risk of clinical VTE from available studies of patients with ICH vary widely (",
"    <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"     table 1",
"    </a>",
"    ), due to differing severities of stroke, differing fractions of ICH patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    prior to stroke onset, differing methods used for anticoagulation reversal, and differing methods to detect VTE (clinically-evident versus asymptomatic by ultrasonography). In the absence of antithrombotic therapy or intermittent pneumatic compression, the frequency of clinical VTE in the first weeks following stroke for acute ICH patients is estimated to be approximately 2 percent overall and approximately 5 percent for those with leg weakness precluding independent ambulation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial comparing elastic stockings alone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/16\">",
"       16",
"      </a>",
"      ] versus elastic stockings plus intermittent pneumatic compression that included 133 ICH patients with and without leg weakness, there were no clinically evident episodes of VTE at 10 days and two (1.5 percent) after 90 days [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/17\">",
"       17",
"      </a>",
"      ]. Asymptomatic VTE were detected by compression ultrasonography in 16 percent of those given elastic stockings alone (three proximal VTE, eight distal VTE) versus 5 percent of those additionally treated with intermittent pneumatic compression (three distal VTE) (p=0.03). The study points out difficulty detecting deep venous thrombosis without ultrasound surveillance, but the cost benefit of aggressive monitoring for subclinical DVT and PE is unknown.",
"     </li>",
"     <li>",
"      In a Japanese study of 52 patients with acute ICH (including nine with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      -associated ICH), 40 percent (n=21) had VTE detected by ultrasonography done two weeks after stroke onset [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/11\">",
"       11",
"      </a>",
"      ]. Nineteen were distal VTE, while two were proximal. VTEs were detected in the paralytic leg in 15 patients, the non-paralytic side in three patients, and in both legs in two patients. The study again pointed out the higher risk of DVT in immobilized legs.",
"     </li>",
"     <li>",
"      VTE was observed in 4 percent of 350 acute ICH patients during three months of observation in combined analysis of the control arms two clinical trials testing recombinant factor VIIa in acute ICH [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three of 66 (5 percent) patients with acute ICH had a fatal PE within 30 days in the population-based Oxfordshire Community Stroke Project [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Of 1,606,000 patients hospitalized in the United States between 1979 and 2003 with a diagnosis of hemorrhagic stroke from the National Hospital Discharge Survey, VTE was also reported as a discharge diagnosis in 1.4 percent and pulmonary embolism in 0.7 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/15\">",
"       15",
"      </a>",
"      ]. No details about the type of hemorrhagic stroke or preventive measures for VTE were provided.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of randomized trial data concerning prevention of VTE in patients with ICH&mdash;only three small randomized trials and one meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/4,17,19,20\">",
"     4,17,19,20",
"    </a>",
"    ] Of note, a randomized trial showed no benefit of thigh-length graduated compression stockings for prevention of VTE in patients with all types of stroke and substantial leg weakness; results for the subgroup of participants with ICH were not reported separately [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Heparin in patients with a prior acute ICH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very few studies are available that have studied the risks and benefits of re-starting prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    after a prior episode of ICH. Most are retrospective. Examples include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small randomized trial compared the ability of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (5000 units SQ three times daily) started at different times after ICH to prevent subsequent VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. Symptomatic PE was reported in 1 of 23 patients (4 percent) when heparin treatment was started four days after onset of ICH compared with 3 of 23 patients (13 percent) who started treatment at 10 days after ICH onset (",
"      <a class=\"graphic graphic_table graphicRef73586 \" href=\"UTD.htm?19/6/19563\">",
"       table 2",
"      </a>",
"      ). Recurrent ICHs were similarly distributed, but their timing in relation to ICH onset and heparin use was not reported. A third group (nonrandomized) of 22 patients with acute ICH was given heparin starting on the second day after ICH; there were no episodes of symptomatic PE or recurrent ICH.",
"     </li>",
"     <li>",
"      A second small randomized trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      40 mg daily started 48 hours after ICH onset versus no antithrombotic therapy reported three asymptomatic VTE detected by ultrasonography among 39 subjects in the enoxaparin group versus one asymptomatic VTE among 36 patients in the control group (",
"      <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study of 91 acute ICH patients observed fewer VTE in those given low-molecular-weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      within 96 hours of ICH onset, with no apparent increase in hematoma enlargement (",
"      <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Intermittent pneumatic compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared the use of elastic stockings with or without intermittent pneumatic compression in 133 acute ICH patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/17\">",
"     17",
"    </a>",
"    ]. A three chamber (ankle, calf, thigh) device with sequential compression was tested in this trial. Key findings of this study include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no clinically evident episodes of VTE in either group during the first 10 days.",
"     </li>",
"     <li>",
"      After three months, there was one clinically evident VTE in each group (1.5 percent).",
"     </li>",
"     <li>",
"      Asymptomatic DVT detected by compression ultrasonography on day 10 was less common (relative risk 0.29, 95% CI 0.08-1.00) in patients who received elastic stockings plus intermittent pneumatic compression (5 percent, 3 of 74, all distal) than in those who received elastic stockings only (16 percent, 11 of 77, 3 proximal and 8 distal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;For prevention of VTE in patients with acute ICH, one randomized study and two",
"    <span class=\"nowrap\">",
"     guidelines/consensus",
"    </span>",
"    statements support the use of graduated compression stockings and intermittent pneumatic compression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/17,23,24\">",
"     17,23,24",
"    </a>",
"    ]. At present, intermittent pneumatic compression should be considered the mainstay for prevention of venous thromboembolism in patients with acute ICH. There are several types of intermittent pneumatic compression devices (eg, multichamber versus monochamber, pressure applied sequentially or uniformly, whole leg versus calf only), and it is not known what type is optimal for VTE prevention in stroke patients. In the only randomized trial in patients with acute ICH, a three chamber device that included thigh compression was used. As noted above, the value of graduated compression stockings has been challenged by negative results of a randomized trial that included patients with acute ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overall benefit versus risks of antithrombotic therapy for prevention of VTE remains uncertain. Extrapolating from patients with acute",
"    <strong>",
"     ischemic",
"    </strong>",
"    stroke, it is likely that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMW heparin, heparinoids, and, to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , reduce the incidence of VTE in patients with an acute ICH. However, the safety of these agents in a setting of acute ICH has yet to be adequately established, and the absolute benefit for VTE prevention is likely to be low if intermittent pneumatic compression prophylaxis is properly used. American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    Stroke Association Stroke Council guideline has recommended that after documentation of cessation of bleeding, low-dose low-molecular-weight or unfractionated heparin may be considered in patients at high risk (mostly bed bound) as early as the first day after ICH onset [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are neither good data nor expert consensus about the optimal treatment of venous thromboembolism (VTE) in patients with acute ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. One review estimated the risk of fatal PE in patients with acute ICH to be about 25 percent for those who were untreated for proximal DVT or nonfatal PE [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/26\">",
"     26",
"    </a>",
"    ]. This risk is clearly too high to deny treatment for VTE to patients with an acute ICH and an otherwise good neurologic prognosis. However, the risks of worsening of an ICH with or without anticoagulation are not fully known, as shown in the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reported rate of recurrent ICH during the initial three months following an acute ICH, in the absence of anticoagulation, is about 1 percent (range 0.4 to 3.0 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/10,29,30\">",
"       10,29,30",
"      </a>",
"      ]. It is uncertain how many of these \"recurrences\" are actually extensions of initial bleeding versus bleeding from a separate site.",
"     </li>",
"     <li>",
"      A theoretical analysis has estimated that anticoagulation increases the risk of recurrent ICH three- to fivefold, with absolute rates of 3 to 5 percent (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Prior ICH'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the above estimates, which have not been confirmed by clinical studies, the risk of recurrent ICH during anticoagulation (3 to 5 percent) appears to be substantially less than that of a fatal PE in patients with an",
"    <span class=\"nowrap\">",
"     acute/resolving",
"    </span>",
"    ICH and a proximal DVT or PE (25 percent). These constructs clearly favor the use of anticoagulation in this setting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    and LMW heparins are highly efficacious for reducing fatal and nonfatal PE in nonstroke patients with proximal DVT",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .) Consequently, heparin, LMW heparin, or heparinoid, followed by the use of reduced intensity of oral anticoagulation for three months may have a favorable benefit-to-risk ratio in selected patients with ICH.",
"   </p>",
"   <p>",
"    The use of inferior vena cava (IVC) filters in this situation has been recommended by some authorities, including the American Heart Association guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/23,32\">",
"     23,32",
"    </a>",
"    ]. However, there are no direct comparisons between these two options (ie, anticoagulation versus IVC filter). The higher rate of long-term complications and lesser efficacy of IVC filters may therefore support the use of anticoagulants for patients who are more than one week from ICH onset [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/26,28\">",
"     26,28",
"    </a>",
"    ], or when IVC placement is not feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with acute ICH and proximal DVT or nonfatal PE and who are &gt;4 days from ICH onset, we recommend treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMW heparin, or heparinoid, followed by the use of reduced intensity of oral anticoagulation (ie, a target INR of 2.0) for a period of three months.",
"   </p>",
"   <p>",
"    There are some exceptions in which anticoagulation may be safely withheld.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with recent ICH, nonmassive pulmonary embolism, adequate cardiopulmonary reserve, and negative serial ultrasonography for proximal DVT, the three month risk of subsequent PE is very low; as a result, withholding anticoagulation in such patients may be acceptable [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For ICH patients with DVT confined to below the knee, withholding anticoagulation is reasonable, providing cardiorespiratory reserve is adequate and serial monitoring to detect proximal extension of the thrombosis can be carried out.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of whether or not the patient is anticoagulated, control of hypertension substantially reduces the risk of recurrent ICH. The potential efficacy of blood pressure lowering in patients not anticoagulated was illustrated in the randomized PROGRESS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/34\">",
"     34",
"    </a>",
"    ]. Lowering the systolic blood pressure by 11 mmHg halved the risk of recurrent ICH among ICH survivors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRIOR ICH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30,000 Americans survive an ICH each year, and several hundred thousand ICH survivors, typically elderly and hypertensive, are at risk for subsequent ischemic vascular events. Use of long-term antiplatelet or anticoagulant drugs in ICH survivors involves a challenging",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    decision, the key elements of which are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rate of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;ICH recurs in survivors at a rate of 2 to 3",
"    <span class=\"nowrap\">",
"     percent/year,",
"    </span>",
"    representing an approximate 10-fold increase in relative risk over the general population and a 2",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    absolute risk increase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3,30,35,36\">",
"     3,30,35,36",
"    </a>",
"    ]. Several factors are associated with the risk of recurrence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The site of the initial ICH may be important. As an example, lobar hemorrhage involving the cerebral cortex, often related to amyloid angiopathy in the very elderly, appears to carry a higher risk of recurrence than deep hemispheric hemorrhage in some [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3,30\">",
"       3,30",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/36\">",
"       36",
"      </a>",
"      ] studies.",
"     </li>",
"     <li>",
"      It seems likely that cerebral microbleeds and severe leukoaraiosis detected by MRI are predictive of recurrence risk. However, there are insufficient clinical data to reliably estimate an individual patient's risk of recurrence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'High risk patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The recurrence risk is also related to reversible factors such as control of preexisting hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of ischemic stroke in ICH survivors is 1 to 3",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3,30,36\">",
"     3,30,36",
"    </a>",
"    ], approximately three times that of the age-matched general population. Based on a common pathogenesis of cerebral small artery disease, ischemic strokes in ICH survivors would be expected to most often be \"lacunar\" infarcts, but there are no clinical studies to support this notion. In addition, limited information is available concerning nonfatal myocardial infarction and other vascular events in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, at least half of recurrent strokes in ICH survivors are recurrent ICHs, occurring at a rate of about 2.5",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    Much less information is available on the rate of recurrence in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Aspirin and warfarin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few clinical data are available concerning the effects of chronic antithrombotic therapy in ICH survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3,22,38,39\">",
"     3,22,38,39",
"    </a>",
"    ]. In one study, anticoagulation given to such patients was associated with a threefold increased risk of recurrent ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/3\">",
"     3",
"    </a>",
"    ]. However, it was not clear from this report whether the initial ICH occurred during anticoagulation. This potentially important distinction is discussed below.",
"   </p>",
"   <p>",
"    Based upon the approximate threefold increased risk of initial ICH associated with achieved INRs of 2.0 to 3.0 in elderly patients, anticoagulation of ICH survivors would be predicted to increase the rate of recurrent ICH, a particularly lethal type of stroke, from a baseline of 2",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    to as high as 6",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H8#H8\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'High risk patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of anticoagulation-associated ICH reflects the underlying rate of spontaneous subclinical microbleeds multiplied by a factor determined by the intensity of anticoagulation. Patients whose initial ICH occurred in the absence of anticoagulation may have a greater tendency for spontaneous microbleeds than those whose ICH was precipitated by anticoagulation. As a result, the accentuated risk of recurrent ICH by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may be less for those who were anticoagulated at the time of the initial ICH than for those who were not (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Management decisions'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In a number of case series, antiplatelet therapy was not associated with a higher risk of recurrent ICH in ICH survivors, but the confidence intervals around the estimates are too wide to be reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. From large randomized trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use is associated with an approximately 40 percent increase in the risk of initial ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Among the general population of elderly people whose ICH risk averages 0.15",
"    <span class=\"nowrap\">",
"     percent/year,",
"    </span>",
"    this relative risk increase translates into a small absolute increase: approximately 1700 elderly patients would need to be treated with aspirin for one year for one \"extra\" ICH to occur. However, in ICH survivors with an average recurrence risk of 2",
"    <span class=\"nowrap\">",
"     percent/year,",
"    </span>",
"    aspirin hypothetically increases the risk of recurrent ICH by about 0.8",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    This risk needs to be balanced against the risk of myocardial infarction and ischemic stroke in individual patients who have or will have an indication for antiplatelet therapy. In such patients ischemic stroke or myocardial infarction may be more common than recurrent ICH [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above constructs are based upon extrapolations of relative risk increases by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for initial ICH, rather than for recurrent ICH, and have not been clinically verified. Nevertheless, they form a logical basis for management decisions that must be made in survivors of ICH in the absence of adequate clinical studies.",
"   </p>",
"   <p>",
"    Efforts to control blood pressure are likely to significantly reduce the risk of recurrent ICH in these patients, although available guidelines do not provide full instruction on this point [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/2\">",
"     2",
"    </a>",
"    ]. In the randomized PROGRESS trial of over 6000 patients with prior cerebral ischemia and a mean baseline blood pressure of",
"    <span class=\"nowrap\">",
"     147/86",
"    </span>",
"    mmHg, a modest reduction of blood pressure of",
"    <span class=\"nowrap\">",
"     9/4",
"    </span>",
"    mmHg decreased the rate of ICH by one-half (1.2 versus 2.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/43\">",
"     43",
"    </a>",
"    ]. The goal blood pressure should be less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=see_link&amp;anchor=H10#H10\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\", section on 'Blood pressure control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     No prior ischemic stroke or clinical coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of ischemic stroke of about 1",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    would presumably be reduced by 0.2",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    following prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , but it is hypothesized that the risk of recurrent ICH would increase by 0.8",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    This would favor withholding aspirin in most ICH survivors without manifest ischemic vascular disease. ICH survivors with subclinical \"lacunar\" infarcts evident on MRI are probably at insufficiently high risk of ischemic stroke to warrant therapy with antiplatelet agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=see_link\">",
"     \"Lacunar infarcts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prior ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy is frequently used following noncardioembolic ischemic stroke, conferring a relative risk reduction of about 20 percent for recurrent ischemic stroke, and an absolute reduction of about 1",
"    <span class=\"nowrap\">",
"     percent/year.",
"    </span>",
"    This benefit would be offset by an estimated increase of about 0.8",
"    <span class=\"nowrap\">",
"     percent/year",
"    </span>",
"    in recurrent ICH, which is typically more neurologically devastating than noncardioembolic ischemic stroke. This analysis favors withholding antiplatelet therapy in this subgroup of patients unless the risk of recurrent ischemic stroke is presumed to be higher than average or there is associated coronary artery disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     AF and not anticoagulated at initial ICH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with atrial fibrillation (AF) who have had an ICH, the estimated incremental absolute increased risk for repeat ICH associated with anticoagulation (4",
"    <span class=\"nowrap\">",
"     percent/year)",
"    </span>",
"    mandates at least a similar reduction in ischemic stroke to favor its use. Consequently, only subgroups of patients with AF at high risk for ischemic stroke (ie, &gt;6",
"    <span class=\"nowrap\">",
"     percent/year)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 3",
"    </a>",
"    ) are likely to benefit, and only those with prior ischemic stroke, whose recurrent stroke rate averages 12",
"    <span class=\"nowrap\">",
"     percent/year,",
"    </span>",
"    are likely to benefit substantially. A decision analysis supports the view that anticoagulation is not of benefit in most ICH survivors; in particular, patients with initial lobar ICH should not be given anticoagulants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recent American Heart Association guideline advocates that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation be avoided in atrial fibrillation patients who survive spontaneous lobar ICH, but that warfarin be considered after nonlobar ICH in the presence of additional risk factors for thromboembolism (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the issue has not been settled [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/44\">",
"     44",
"    </a>",
"    ], if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is to be given to ICH survivors with AF, a target INR range of 2.0 to 2.5, the lower end of the recommended INR target range of 2.0 to 3.0 is recommended. Aggressive control of blood pressure is particularly critical for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     AF and anticoagulated at initial ICH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the reasoning outlined above, the incremental absolute increase in ICH recurrence may be less when ICH followed anticoagulation than for those who were not anticoagulated at the time of the index event. However, pending additional data [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/37\">",
"     37",
"    </a>",
"    ], anticoagulation might best be reserved for those at the highest risk of ischemic stroke (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"UTD.htm?39/45/40668\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Resumption of anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While restarting anticoagulation (or not) as well as the most reasonable time to restart anticoagulation are both highly controversial, understanding the following issues might help in handling this dilemma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       In favor of resumption of anticoagulation",
"      </strong>",
"       Deep hemispheric bleeding rather than lobar bleeding; blood pressure, glucose, lipid metabolism sufficiently controlled; high likelihood of recurrent thrombosis according to the patient&rsquo;s CHADS2 score; prior good control of anticoagulation intensity; cause of ICH unrelated to the use of anticoagulation (eg, AV malformation). Anticoagulation should be restarted at 7 to 14 days after the event if the patient is otherwise stable in order to minimize the risk of recurrent thrombosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Against resumption of anticoagulation",
"      </strong>",
"       Lobar rather than deep hemispheric bleeding, especially if clear signs of microangiopathy are present; blood pressure not well controlled; lower risk of recurrent thrombosis according to the CHADS2 score; prior poor control of anticoagulation intensity. If the decision is to retreat with anticoagulation, it should be restarted at 10 to 30 weeks after the initial ICH to minimize the risk of rebleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only those ICH survivors with an exceptionally high risk for atherothrombotic events should be treated with antiplatelet drugs, and only those with very high risk for cardioembolic stroke (ie, prosthetic valves, dilated cardiomyopathy, documented intracardiac thrombus) should be treated with anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/23\">",
"     23",
"    </a>",
"    ]. While stratification of the risk of recurrent ICH according to lobar versus nonlobar location of initial ICH has been advocated, data are not entirely consistent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study suggested waiting one to two months before resumption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8089/abstract/48\">",
"     48",
"    </a>",
"    ], but this applied mostly to patients with atrial fibrillation alone. In patients with mechanical valves or evidence of intracardiac thrombus, we suggest waiting for 7 to 10 days and then selecting a target INR range of 2.0 to 2.5. This level represents the lower end of the generally recommended INR target range of 2.0 to 3.0. Aggressive control of blood pressure is particularly critical in such patients to reduce the risk of subsequent bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8953649\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute or prior intracerebral hemorrhage (ICH) have generally been excluded from antithrombotic trials because of fears of worsening central nervous system bleeding. Consequently, the efficacy and safety of anticoagulants and antiplatelet agents in patients with acute or prior ICH are derived mainly from weaker observational data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute ICH",
"      </strong>",
"      &mdash; Active bleeding into the brain is usually confined to the first six hours following spontaneous ICH, with 10 to 15 percent of patients showing hematoma enlargement between 6 and 24 hours from the onset of ICH, while clinically evident deep vein thrombosis is typically delayed for more than one week after stroke, and has been reported in 2 to 15 percent of patients with ICH (",
"      <a class=\"graphic graphic_table graphicRef57706 \" href=\"UTD.htm?1/63/2046\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Acute ICH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Intermittent pneumatic compression should be considered the mainstay for prevention of venous thromboembolism in patients with acute ICH.",
"     </li>",
"     <li>",
"      In patients with acute ICH and proximal DVT or nonfatal PE who are &gt;4 days from ICH onset, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , LMW heparin, or heparinoid, followed by the use of reduced intensity of oral anticoagulation (ie, a target INR of 2.0) for a period of three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Prior ICH",
"      </strong>",
"      &mdash; Use of long-term antiplatelet or anticoagulant drugs in ICH survivors involves a challenging",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      decision. Accordingly, only those ICH survivors with an exceptionally high risk for atherothrombotic events should be treated with antiplatelet drugs, and only those with very high risk for cardioembolic stroke should be treated with anticoagulation. Aggressive control of blood pressure is particularly critical to reduce the risk of subsequent bleeding. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prior ICH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/1\">",
"      Qureshi AI, Tuhrim S, Broderick JP, et al. Spontaneous intracerebral hemorrhage. N Engl J Med 2001; 344:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/2\">",
"      Smith EE, Liang L, Hernandez A, et al. Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology 2009; 73:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/3\">",
"      Vermeer SE, Algra A, Franke CL, et al. Long-term prognosis after recovery from primary intracerebral hemorrhage. Neurology 2002; 59:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/4\">",
"      Paciaroni M, Agnelli G, Venti M, et al. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies. J Thromb Haemost 2011; 9:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/5\">",
"      Fujii Y, Tanaka R, Takeuchi S, et al. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg 1994; 80:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/6\">",
"      Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/7\">",
"      Mayer SA, Sacco RL, Shi T, Mohr JP. Neurologic deterioration in noncomatose patients with supratentorial intracerebral hemorrhage. Neurology 1994; 44:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/8\">",
"      Wijdicks EF, Fulgham JR. Acute fatal deterioration in putaminal hemorrhage. Stroke 1995; 26:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/9\">",
"      Bae HG, Lee KS, Yun IG, et al. Rapid expansion of hypertensive intracerebral hemorrhage. Neurosurgery 1992; 31:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/10\">",
"      Bae H, Jeong D, Doh J, et al. Recurrence of bleeding in patients with hypertensive intracerebral hemorrhage. Cerebrovasc Dis 1999; 9:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/11\">",
"      Ogata T, Yasaka M, Wakugawa Y, et al. Deep venous thrombosis after acute intracerebral hemorrhage. J Neurol Sci 2008; 272:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/12\">",
"      Christensen MC, Dawson J, Vincent C. Risk of thromboembolic complications after intracerebral hemorrhage according to ethnicity. Adv Ther 2008; 25:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/13\">",
"      Kawase K, Okazaki S, Toyoda K, et al. Sex difference in the prevalence of deep-vein thrombosis in Japanese patients with acute intracerebral hemorrhage. Cerebrovasc Dis 2009; 27:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/14\">",
"      Gregory PC, Kuhlemeier KV. Prevalence of venous thromboembolism in acute hemorrhagic and thromboembolic stroke. Am J Phys Med Rehabil 2003; 82:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/15\">",
"      Skaf E, Stein PD, Beemath A, et al. Venous thromboembolism in patients with ischemic and hemorrhagic stroke. Am J Cardiol 2005; 96:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/16\">",
"      CLOTS Trials Collaboration, Dennis M, Sandercock PA, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009; 373:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/17\">",
"      Lacut K, Bressollette L, Le Gal G, et al. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology 2005; 65:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/18\">",
"      Counsell C, Boonyakarnkul S, Dennis M, et al. Intracerebral haemorrhage in the Oxfordshire Community Stroke Project. Cerebrovasc Dis 1995; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/19\">",
"      Dickmann U, Voth E, Schicha H, et al. Heparin therapy, deep-vein thrombosis and pulmonary embolism after intracerebral hemorrhage. Klin Wochenschr 1988; 66:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/20\">",
"      Orken DN, Kenangil G, Ozkurt H, et al. Prevention of deep venous thrombosis and pulmonary embolism in patients with acute intracerebral hemorrhage. Neurologist 2009; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/21\">",
"      Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry 1991; 54:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/22\">",
"      Iwuchukwu IO, Mckinney J, Rosenberg M. DVT prophylaxis and risk of bleeding in intracerebral hemorrhage. Ann Neurol 2009; 66:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/23\">",
"      Broderick J, Connolly S, Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/24\">",
"      Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e195S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/25\">",
"      Wijdicks EF, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997; 72:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/26\">",
"      Kelly J, Hunt BJ, Lewis RR, Rudd A. Anticoagulation or inferior vena cava filter placement for patients with primary intracerebral hemorrhage developing venous thromboembolism? Stroke 2003; 34:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/27\">",
"      Cohen DL. Treating thrombotic complications in patients with primary intracerebral haemorrhage. J R Coll Physicians Lond 1998; 32:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/28\">",
"      Barton AL, Dudley NJ. Caval filter placement for pulmonary embolism in a patient with a deep vein thrombosis and primary intracerebral haemorrhage. Age Ageing 2002; 31:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/29\">",
"      Passero S, Burgalassi L, D'Andrea P, Battistini N. Recurrence of bleeding in patients with primary intracerebral hemorrhage. Stroke 1995; 26:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/30\">",
"      Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology 2001; 56:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/31\">",
"      Eckman MH, Rosand J, Knudsen KA, et al. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke 2003; 34:1710.",
"     </a>",
"    </li>",
"    <li>",
"     Wijman CA, Kase CS. Intracerebral hemorrhage. Medical considerations. In: Stroke. Pathophysiology, Diagnosis, and Management, 3rd ed, Barnett  HJ, Mohr JP, Stein BM, Yatsu FM (Eds), Churchill Livingstone, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/33\">",
"      Stein PD, Hull RD, Raskob GE. Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests. Am J Med 2000; 109:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/34\">",
"      Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004; 35:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/35\">",
"      Saloheimo P, Juvela S, Hillbom M. Use of aspirin, epistaxis, and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 2001; 32:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/36\">",
"      Zia E, Engstr&ouml;m G, Svensson PJ, et al. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009; 40:3567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/37\">",
"      Claassen DO, Kazemi N, Zubkov AY, et al. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol 2008; 65:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/38\">",
"      Butler AC, Tait RC. Restarting anticoagulation in prosthetic heart valve patients after intracranial haemorrhage: a 2-year follow-up. Br J Haematol 1998; 103:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/39\">",
"      Viswanathan A, Rakich SM, Engel C, et al. Antiplatelet use after intracerebral hemorrhage. Neurology 2006; 66:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/40\">",
"      Flynn RW, MacDonald TM, Murray GD, et al. Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage. Stroke 2010; 41:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/41\">",
"      He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998; 280:1930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/42\">",
"      Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/43\">",
"      PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/44\">",
"      Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/45\">",
"      Molina CA, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke 2011; 42:3665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/46\">",
"      Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke 2011; 42:3661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/47\">",
"      Shulman S. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: No. Stroke 2011; 42:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8089/abstract/48\">",
"      Majeed A, Kim YK, Roberts RS, et al. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke 2010; 41:2860.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1323 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8089=[""].join("\n");
var outline_f7_57_8089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8953649\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recurrent bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Venous thromboembolism in acute ICH patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Heparin in patients with a prior acute ICH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Intermittent pneumatic compression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRIOR ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rate of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Aspirin and warfarin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management decisions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - No prior ischemic stroke or clinical coronary disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prior ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - AF and not anticoagulated at initial ICH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - AF and anticoagulated at initial ICH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8953649\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/63/2046\" title=\"table 1\">",
"      VTE frequency in acute ICH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/6/19563\" title=\"table 2\">",
"      Heparin intracerebral hem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/45/40668\" title=\"table 3\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37001?source=related_link\">",
"      Cerebral amyloid angiopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4026?source=related_link\">",
"      Lacunar infarcts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8090="Acute compartment syndrome of the extremities";
var content_f7_57_8090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute compartment syndrome of the extremities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Andrea Stracciolini, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8090/contributors\">",
"     E. Mark Hammerberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/57/8090/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/57/8090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups of the human limbs are divided into sections, or compartments, formed by strong, unyielding fascial membranes. Compartment syndrome occurs when increased pressure within a compartment compromises the circulation and function of the tissues within that space [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compartment syndrome may occur acutely, often following trauma, or as a chronic syndrome, seen most often in athletes, that presents as insidious pain. Acute compartment syndrome (ACS) is a surgical emergency.",
"   </p>",
"   <p>",
"    The pathophysiology, risk factors, diagnosis, and management of acute compartment syndrome in the extremities are reviewed here. Chronic exertional compartment syndrome, fasciotomy techniques and postsurgical care, and abdominal compartment syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28215?source=see_link\">",
"     \"Chronic exertional compartment syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link\">",
"     \"Lower extremity fasciotomy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute compartment syndrome (ACS) most often develops soon after significant trauma, particularly involving long bone fractures. However, ACS may also occur following minor trauma or from nontraumatic causes. Common sites include the leg and forearm [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. ACS can also occur in the foot, thigh, and gluteal region.",
"   </p>",
"   <p>",
"    ACS is seen more often in patients under 35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"     4",
"    </a>",
"    ]. Young men appear to have the highest incidence, particularly after fractures of the tibial diaphysis and distal radius. This may be explained by the relatively larger muscle mass of men contained within fascial compartments that do not change in size once growth is complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Long bone fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures account for approximately 75 percent of cases of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. Risk increases with comminuted fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/6\">",
"     6",
"    </a>",
"    ]. The tibia is involved most often, with ACS developing in approximately 1 to 10 percent of such fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,7-9\">",
"     2,7-9",
"    </a>",
"    ]. The bones of the forearm are involved second most often. Among children, supracondylar fractures are a common cause. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pediatric considerations'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one case series of 164 patients with ACS, fracture was the cause in 69 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"     4",
"    </a>",
"    ]. Fractures of the tibial diaphysis (36 percent) and the distal radius (9.8 percent) accounted for the largest share. According to this case series, approximately 20 percent of tibial diaphyseal fractures that lead to ACS are sustained during sports [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"     4",
"    </a>",
"    ]. Soft tissue injury without a fracture was the cause in 23 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=see_link\">",
"     \"Overview of tibial fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=see_link\">",
"     \"Distal radius fractures in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another case series reported on 113 patients with ACS over an eight year period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/10\">",
"     10",
"    </a>",
"    ]. The authors found that cases of ACS without a fracture were at significantly greater risk for delayed diagnosis and treatment (ie, fasciotomy). At fasciotomy, 20 percent of patients without a fracture had muscle necrosis requiring debridement, compared with 8 percent of patients with a fracture.",
"   </p>",
"   <p>",
"    Both closed and open fracture treatment can increase compartment pressure and the risk for ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment of fractures should be performed as soon as possible, but clinicians should monitor patients for signs of ACS following these procedures.",
"   </p>",
"   <p>",
"    Closed fracture reduction decreases the volume and alters the configuration of tissue compartments increasing compartment pressures. According to one prospective observational study involving distal radius fractures, pressures peak immediately after reduction and before a cast is split [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/11\">",
"     11",
"    </a>",
"    ]. After splitting, pressures drop precipitously. A second pressure peak is seen approximately four hours after reduction and dissipates more gradually over several hours. Overly constrictive casts placed at any time during fracture management can lead to ACS. In addition, even non-constricting casts can contribute to ACS if there is significant swelling after the reduction.",
"   </p>",
"   <p>",
"    Open fracture reduction and fixation also lead to increases in compartment pressures. Pressures during intramedullary nailing of the tibia appear to peak during the procedure and decrease over the following 36 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/12\">",
"     12",
"    </a>",
"    ]. Compartment pressures following volar plating of distal radius fractures appear to diminish substantially during the 24 hour period following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/13\">",
"     13",
"    </a>",
"    ]. The risk of ACS increases with the duration of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trauma without fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other forms of trauma not involving a fracture can predispose a patient to ACS. Possible causes include forceful direct trauma to a tissue compartment (eg, crush injury), severe thermal burns, overly constrictive bandages (usually circumferential), penetrating trauma, injury to vascular structures in the extremities, and in some cases, even minor injuries. Patients with a bleeding diathesis and those who continue to use an injured limb are at increased risk.",
"   </p>",
"   <p>",
"    Thermal injuries, particularly full-thickness burns, can cause ACS secondary to tissue constriction, eschar, and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14\">",
"     14",
"    </a>",
"    ]. The large fluid shifts associated with major burns also contribute. In such cases abdominal compartment syndrome is a major concern. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unconscious or obtunded patients with prolonged limb compression, either during surgery or due to recreational drug abuse, can develop ACS secondary to soft tissue injury and swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Victims of penetrating extremity trauma are also susceptible to developing ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients who develop rhabdomyolysis for any reason are at increased risk for ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular, particularly arterial, injury is an important cause of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. Arterial bleeding increases compartment pressures and muscle deprived of arterial blood flow becomes ischemic and prone to reperfusion injury, which in turn causes swelling and a further increase in compartment pressures. In addition, muscle that has sustained a previous ischemic insult is less tolerant of increased tissue pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/19\">",
"     19",
"    </a>",
"    ]. Venous injury (eg, traumatic deep vein harvest, direct vein trauma) is also associated with an increased risk of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reports of minor trauma leading to ACS include cases involving the peroneal compartment following a minor ankle inversion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/22\">",
"     22",
"    </a>",
"    ], compartments of the foot after an inversion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/23\">",
"     23",
"    </a>",
"    ], and the upper extremity after it was struck by a baseball [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/24\">",
"     24",
"    </a>",
"    ]. Intramuscular hemorrhage following minor trauma in patients taking anticoagulants also increases the risk for developing ACS. Some researchers believe that relatively larger muscle volumes may be a risk factor for ACS, which explains why men are generally more susceptible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nontraumatic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACS from nontraumatic causes occurs less frequently. It may be related to ischemia-reperfusion injury, thrombosis, bleeding disorders, vascular disease, nephrotic syndrome (or other conditions that decrease serum osmolarity), certain animal envenomations and bites, extravasation of IV fluids, injection of recreational drugs, and prolonged limb compression (eg, following severe drug or alcohol intoxication or poor positioning during surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,25-27\">",
"     2,25-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Revascularization procedures and treatments, such as extremity bypass surgery, embolectomy, and thrombolysis, increase the risk for ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/28\">",
"     28",
"    </a>",
"    ]. This phenomenon is known as postischemic compartment syndrome and is due to tissue swelling from reperfusion. The syndrome can occur from a few hours following the procedure up to several days later [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/29\">",
"     29",
"    </a>",
"    ]. Residual effects from anaesthesia and postoperative sedation can make early detection of ACS more difficult immediately after surgery.",
"   </p>",
"   <p>",
"    Anticoagulation following surgery, such as prophylaxis against deep vein thrombosis, may contribute to ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/30\">",
"     30",
"    </a>",
"    ]. Symptoms can mimic postoperative pain making the diagnosis difficult. Iatrogenic injury of arteries or veins in anticoagulated patients is another potential cause [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/31\">",
"     31",
"    </a>",
"    ]. The use of intraaortic balloon pumps has been associated with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug abusers can develop ACS following intravenous or inadvertent intraarterial injection of drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ACS may arise as a complication of underlying disease. As examples, there are case reports of ACS in a 13-year-old boy with a large osteochondroma arising from the fibula that compromised blood flow in the lateral and posterior leg compartments [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/35\">",
"     35",
"    </a>",
"    ] and in other children following episodes of myositis and fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/26\">",
"     26",
"    </a>",
"    ]. Group A streptococcus infections of muscle can be complicated by ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intramuscular hemorrhage in patients treated chronically with anticoagulants can progress to ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. In rare cases, phlegmasia cerulea dolens has been associated with ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=see_link&amp;anchor=H7#H7\">",
"     \"Approach to the diagnosis and therapy of lower extremity deep vein thrombosis\", section on 'Phlegmasia cerulea dolens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of surgical procedures involving the leg (eg, saphenous vein harvest) have been associated with ACS in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple explanations for the complex pathophysiology of ACS exist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/43\">",
"     43",
"    </a>",
"    ]. In all cases, the final common pathway is cellular anoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14\">",
"     14",
"    </a>",
"    ]. A prerequisite for the development of increased compartment pressure is a fascial structure that prevents adequate expansion of tissue volume to compensate for an increase in fluid.",
"   </p>",
"   <p>",
"    Perhaps the most widely believed hypothesis for the pathophysiology of ACS is the arteriovenous pressure gradient theory [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2\">",
"     2",
"    </a>",
"    ]. The premise of this theory is that ischemia begins when local blood flow cannot meet the metabolic demands of surrounding tissue. As compartment pressure rises, venous outflow is reduced and venous pressure rises, leading to a decrease in the arteriovenous pressure gradient. Ultimately arteriolar pressure is insufficient to overcome compartment pressure and blood is shunted away from intracompartmental tissues. Arterioles collapse when tissue pressure exceeds end-arteriolar pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/44\">",
"     44",
"    </a>",
"    ]. Inadequate venous drainage results in tissue edema and a rise in interstitial pressure. Lymphatic drainage may compensate in part initially, but is soon overwhelmed.",
"   </p>",
"   <p>",
"    Compartment pressures capable of compromising perfusion develop when they rise to within 10 to 30 mmHg of diastolic pressure; muscle oxygenation decreases as tissue pressure approaches mean arterial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14,45,46\">",
"     14,45,46",
"    </a>",
"    ]. Therefore, ACS develops based upon both compartment and systemic blood pressures. As an example, compared to a normotensive patient, a patient with hypotension is less likely to tolerate any given increase in tissue pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANATOMIC COMPARTMENTS AND RELATED CLINICAL SIGNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute compartment syndrome (ACS) can occur in any distinct anatomic compartment bound by unyielding fascial membranes. ACS has been described in the upper extremity (primarily the forearm), lower extremity (primarily the leg), hand, foot, buttock, abdomen, thorax, and orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/23,43,47-49\">",
"     23,43,47-49",
"    </a>",
"    ]. Abdominal compartment syndrome is discussed separately. The compartments of the extremities are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lower leg is a common site for ACS and is comprised of four compartments (",
"    <a class=\"graphic graphic_figure graphicRef59437 \" href=\"UTD.htm?25/33/26137\">",
"     figure 1",
"    </a>",
"    ). These compartments are the anterior, lateral, deep posterior, and superficial posterior. Below are included descriptions of possible neurologic findings associated with ACS, but it is important to note that nerve injuries proximal to the affected compartment may also account for such deficits.",
"   </p>",
"   <p>",
"    The anterior compartment of the leg is the most common site for ACS. It contains the four extensor muscles of the foot, the anterior tibial artery, and the deep peroneal nerve (",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"UTD.htm?41/27/42424\">",
"     figure 2",
"    </a>",
"    ). Signs of ACS affecting the anterior compartment include loss of sensation between the first (ie, great) and second toes and weakness of foot dorsiflexion. Late sequelae include foot drop, claw foot, and deep peroneal nerve dysfunction. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lateral compartment of the leg contains the muscles responsible for foot eversion and some degree of plantar flexion (ie, peroneus brevis, peroneus longus), the peroneal artery, the superficial peroneal nerve, and the proximal portion of the deep peroneal nerve. Increased pressure in the lateral compartment may produce a deep peroneal nerve deficit, which manifests as weakness in dorsiflexion and inversion of the foot and sensory loss in the web space between the great toe and the adjacent toe. The superficial peroneal nerve also travels through this compartment and supplies sensation to the lower leg and the dorsum of the foot.",
"   </p>",
"   <p>",
"    The deep posterior compartment contains muscles that aid in foot plantar flexion, as well as the posterior tibial artery, peroneal artery, and the tibial nerve. Increased pressure in this compartment may cause plantar hypesthesia, weakness of toe flexion, and pain with passive extension of the toes.",
"   </p>",
"   <p>",
"    The superficial posterior compartment contains the major muscles of plantar flexion (ie, gastrocnemius, soleus). No major arteries or nerves travel in this compartment. Therefore, of the four leg compartments, the superficial posterior is least likely to develop ACS. Pain and a palpably tense and tender compartment suggest the diagnosis.",
"   </p>",
"   <p>",
"    The forearm has four compartments: the deep and superficial volar compartments, the dorsal compartment, and the lateral compartment (",
"    <a class=\"graphic graphic_figure graphicRef59437 \" href=\"UTD.htm?25/33/26137\">",
"     figure 1",
"    </a>",
"    ). The volar compartment contains the digital flexors and the dorsal compartment contains the digital extensors. The volar compartments are at highest risk for developing ACS following trauma. The most frequent injuries associated with ACS in the forearm are supracondylar humerus fractures in children and distal radius fractures in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/8,45,50,51\">",
"     8,45,50,51",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pediatric considerations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The deep volar compartment usually develops the highest interstitial pressures with ACS of the forearm and thus the flexor digitorum profundus (responsible for distal interphalangeal joint flexion) and the flexor pollicis longus (responsible for interphalangeal joint flexion of the thumb) muscles are most often affected [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/50\">",
"     50",
"    </a>",
"    ]. The flexor digitorum superficialis (responsible for proximal interphalangeal joint flexion) and pronator teres are affected less often, while the wrist flexors and extensors and the brachioradialis are least likely to be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The arm has two relatively large compartments, the anterior and posterior. These compartments tolerate relatively large fluid volumes, thereby limiting the rise in compartment pressure and minimizing the risk of ACS. The anterior compartment contains the elbow flexor muscles (biceps brachii, brachialis) and the ulnar and median nerves. The posterior compartment contains the elbow extensor muscles (triceps) and the radial nerve.",
"   </p>",
"   <p>",
"    ACS rarely develops in the thigh, but may do so following major trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/52\">",
"     52",
"    </a>",
"    ]. The thigh has three large compartments, the anterior, posterior, and medial:",
"   </p>",
"   <p>",
"    The anterior compartment contains the knee extensors (",
"    <a class=\"graphic graphic_figure graphicRef56894 \" href=\"UTD.htm?35/14/36071\">",
"     figure 3",
"    </a>",
"    ). ACS of the anterior compartment may manifest as pain with passive knee flexion while the hip is held in extension; inability to extend the knee; or sensory deficits involving the lateral, anterior, or medial thigh (cutaneous branches of femoral nerve) or involving the medial calf and foot (saphenous nerve).",
"   </p>",
"   <p>",
"    The posterior compartment contains the knee flexors. ACS of the posterior compartment may manifest as pain with passive knee extension while the hip is held in flexion; inability to flex the knee, plantar flex the ankle, or dorsiflex the great toe; or sensory deficits involving either the dorsum or plantar surface of the foot or the great toe web space (peroneal nerve).",
"   </p>",
"   <p>",
"    The medial compartment contains the hip adductors. ACS of the medial compartment may manifest as pain with passive hip abduction while the knee is held in extension; inability to adduct the hip; or sensory deficits at the proximal medial thigh (obturator nerve).",
"   </p>",
"   <p>",
"    The compartments of the foot are described separately. Compartments in the hand and gluteal region are also susceptible to ACS, but such cases are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H16956414#H16956414\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Foot'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H284706702#H284706702\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Buttock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of acute compartment syndrome (ACS) generally appear in a stepwise fashion, although the timing of the appearance of specific findings varies (",
"    <a class=\"graphic graphic_figure graphicRef59437 \" href=\"UTD.htm?25/33/26137\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,14,53,54\">",
"     2,14,53,54",
"    </a>",
"    ]. Important clues to the development of ACS include rapid progression of symptoms and signs over a few hours and the presence of multiple findings consistent with the diagnosis in a patient at risk. Therefore, serial evaluation is of great importance in patients at risk for ACS. However, the limitations of the physical examination for identifying ACS must be emphasized;",
"    <strong>",
"     any",
"    </strong>",
"    tense painful muscle compartment represents a possible ACS and a definitive diagnosis of ACS can",
"    <strong>",
"     only",
"    </strong>",
"    be made by measuring compartment pressures. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Measurement of compartment pressures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Symptoms of ACS can include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain out of proportion to apparent injury (early and common finding)",
"     </li>",
"     <li>",
"      Persistent deep ache or burning pain",
"     </li>",
"     <li>",
"      Paresthesias (onset within approximately 30 minutes to two hours of ACS; suggests ischemic nerve dysfunction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination findings suggestive of ACS include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain with passive stretch of muscles in the affected compartment (early finding)",
"     </li>",
"     <li>",
"      Tense compartment with a firm \"wood-like\" feeling",
"     </li>",
"     <li>",
"      Pallor from vascular insufficiency (uncommon)",
"     </li>",
"     <li>",
"      Diminished sensation",
"     </li>",
"     <li>",
"      Muscle weakness (onset within approximately two to four hours of ACS)",
"     </li>",
"     <li>",
"      Paralysis (late finding)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The classic findings associated with arterial insufficiency are often described as signs of ACS, but this is inaccurate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/55\">",
"     55",
"    </a>",
"    ]. Of the five classic signs (pain, pallor, pulselessness, paresthesias, paralysis), only pain is commonly associated with compartment syndrome, particularly in its early stages. Paresthesias may also occur.",
"   </p>",
"   <p>",
"    Many authors describe the importance of the common clinical symptoms and signs described above in diagnosing ACS. However, data supporting the accuracy of these findings is limited; each may be unreliable in some circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. A systematic review of four studies of ACS associated with tibial fracture found common clinical findings to have poor sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/56\">",
"     56",
"    </a>",
"    ]. A study using fresh cadavers found that palpation of leg compartments was neither sensitive nor specific for detecting substantial elevations in compartment pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/57\">",
"     57",
"    </a>",
"    ]. Therefore, compartment pressure measurements are necessary for a definitive diagnosis.",
"   </p>",
"   <p>",
"    Pain \"out of proportion to injury\" is often described as an early and sensitive sign of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/8,14,53\">",
"     8,14,53",
"    </a>",
"    ]. Nevertheless, pain can be nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2\">",
"     2",
"    </a>",
"    ]. Most patients at risk for ACS have sustained trauma, and a fracture or an injury to a nerve or soft tissue may be the source of pain. Severe injuries can also distract patients from pain that stems from an ACS. Furthermore, young children, obtunded or critically ill patients, and those emerging from general anesthesia or who were treated with nerve blocks cannot clearly convey the presence of severe or increasing pain.",
"   </p>",
"   <p>",
"    Pain in response to passive stretching of muscles within the affected compartment is widely described as a sensitive early sign of ACS, but it too may be unreliable in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/58\">",
"     58",
"    </a>",
"    ]. Palpable tenseness is a crude indicator of increased compartment pressure and cannot be used to assess the deep posterior compartment of the leg.",
"   </p>",
"   <p>",
"    The presence of neurologic symptoms, such as paresthesias can be confusing because peripheral nerve injury may result directly from trauma or from an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14\">",
"     14",
"    </a>",
"    ]. Sensory deficits typically precede motor deficits and manifest distal to the involved compartment. Some feel that the loss of two-point discrimination is more typical in ACS than in raised intracompartmental pressure alone without ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/20,59\">",
"     20,59",
"    </a>",
"    ]. Again, the limited accuracy of the physical examination for identifying ACS should be emphasized here. In the presence of a painful tense muscle compartment, obtaining compartment pressure measurements is far more important than discerning degrees of relative weakness or sensory loss.",
"   </p>",
"   <p>",
"    Muscle weakness can be difficult to assess in the traumatized patient, patients receiving sedating medications, and patients with altered mental status, and may be attributable to pain, fracture, direct soft tissue injury, peripheral or central nerve injury, or ACS. Of note, muscle weakness or paresis is a late finding of ACS and suggests permanent muscle damage.",
"   </p>",
"   <p>",
"    Several common misconceptions exist pertaining to the clinical diagnosis of ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/2,55\">",
"     2,55",
"    </a>",
"    ]. Clinicians should be aware that ACS can occur in the presence of open fractures as these may",
"    <strong>",
"     not",
"    </strong>",
"    necessarily decompress elevated compartment pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/7\">",
"     7",
"    </a>",
"    ]. Moreover, ACS can occur without a fracture (or a crush injury). The diagnosis is often delayed because clinicians fail to consider ACS in patients without a fracture. Arterial pulses and normal capillary refill can persist despite the presence of a prolonged, severe ACS. Pulse oximetry is an insensitive instrument for diagnosis and should not be relied upon [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Left untreated, ACS can result in muscle contracture, sensory deficits, paralysis, infection, fracture nonunion, and possibly limb amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"     4",
"    </a>",
"    ]. Rhabdomyolysis may occur with muscle ischemia, resulting in myoglobinuria and possible renal failure necessitating dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512176#H11512176\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute compartment syndrome (ACS) is diagnosed on the basis of clinical findings and the measurement of compartment pressures. Laboratory values are not used for diagnosis, but serum creatine kinase (CK) rises as muscle injury develops. Conversely, CK is elevated in patients with rhabdomyolysis, which may go on to cause ACS. Myoglobinuria can develop within four hours of the onset of ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF COMPARTMENT PRESSURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compartment pressures should be measured whenever a clinician suspects ACS based upon the patient's risk factors and clinical findings, namely a painful tense muscle compartment. Measuring compartment pressures in patients at risk for developing ACS entails no major complications, while not doing so may lead to a missed diagnosis and permanent deformity or dysfunction of the extremity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/59\">",
"     59",
"    </a>",
"    ]. Compartment pressure testing may be unnecessary if the diagnosis is clinically obvious. Conversely, repeat measurements may be necessary in some patients as clinical conditions change (eg, worsening hypotension). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical features and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In some cases, it can be especially difficult to determine whether the patient is developing signs of ACS. Young children, obtunded or critically ill patients, and those emerging from general anaesthesia can neither cooperate with a physical examination nor can they clearly convey the presence of severe or increasing pain. Critically ill trauma patients appear to be at particularly high risk and should be monitored closely [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/62\">",
"     62",
"    </a>",
"    ]. If ACS is suspected in such patients on the basis of risk factors or clinical findings, most authors agree that compartment pressure measurements should be obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/63\">",
"     63",
"    </a>",
"    ]. Measurement may also be needed in patients with regional or epidural nerve blocks or equivocal clinical findings who are at risk for ACS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Direct measurement techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although multiple techniques for direct compartment pressure measurement have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/45,64-66\">",
"     45,64-66",
"    </a>",
"    ], three methods have been used most frequently: a handheld manometer (eg, Stryker&trade; device), a simple needle manometer system, and the wick or slit catheter technique. Both manometer methods involve injecting a small quantity of saline into a closed compartment and measuring the resistance from tissue pressure. The hand-held manometer method is used most often because it is portable, simple, and accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/67\">",
"     67",
"    </a>",
"    ]. The slit catheter technique involves inserting a catheter into the compartment and monitoring the pressure via a transducer connected to a pressure amplifier and recorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to an unblinded observational study, these methods produce similar results but may not be reliable in all settings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/69\">",
"     69",
"    </a>",
"    ]. The authors of this study emphasized the importance of interpreting measurements in light of clinical findings. A laboratory study found that simple 18-gauge needles, side-ported needles, and slit catheters all provide equivalent measurements of intracompartmental pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/70\">",
"     70",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Eighteen-gauge needles can be attached easily to an arterial pressure monitor to measure compartment pressures. This technique can prevent potential delays in diagnosis if for example a Stryker&trade; hand-held monitor cannot be located",
"   </p>",
"   <p>",
"    Whichever method is used to measure compartment pressures, accuracy depends upon proper calibration of the measuring device and placement of the needle or pressure sensor close to the site of fracture or injury. Accuracy decreases the further the measurement is taken from the fracture site [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interpretation of measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pressure of a tissue compartment falls between 0 and 8 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/72\">",
"     72",
"    </a>",
"    ]. Clinical findings associated with ACS generally correlate with the degree to which tissue pressure within the affected compartment approaches systemic blood pressures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capillary blood flow becomes compromised when tissue pressure increases to within 25 to 30 mmHg of mean arterial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain may develop as tissue pressures reach between 20 and 30 mmHg.",
"     </li>",
"     <li>",
"      Ischemia occurs when tissue pressures approach diastolic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These values are approximations; the pressure necessary for injury varies depending upon clinical circumstance. As examples, higher compartment pressures may be necessary before injury occurs to peripheral nerves in patients with systemic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/76\">",
"     76",
"    </a>",
"    ], while ACS may develop at lower pressures in those with hypotension or peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/55,77\">",
"     55,77",
"    </a>",
"    ]. Traumatized tissue has increased metabolic demands and is therefore more susceptible to further injury from ischemia secondary to ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/78\">",
"     78",
"    </a>",
"    ]. In one case series involving 18 patients with confirmed ACS of the leg, preoperative tissue measurements ranged from 28 mmHg to 47 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many surgeons involved in trauma care use a threshold based upon the difference between systemic blood pressures and compartment pressures to diagnose ACS. These experts believe that if the difference between the diastolic or mean arterial pressure and the compartment pressure falls below a specific value perfusion pressure becomes compromised and ACS can develop. In addition, many believe the use of absolute measurements leads to unnecessary fasciotomies, or in some cases failure to perform needed fasciotomies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We concur with this approach and suggest that a difference between the diastolic blood pressure and the compartment pressure (delta pressure) of 30 mmHg or less be used as the threshold for diagnosing ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. The delta pressure is found by subtracting the compartment pressure from the diastolic pressure. Many clinicians use the delta pressure of 30 mmHg to determine the need for fasciotomy, while others use a difference of 20 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/14,71\">",
"     14,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACS delta pressure = diastolic blood pressure  measured compartment pressure",
"     </li>",
"     <li>",
"      ACS delta pressure &lt;20 to 30 mmHg indicates need for fasciotomy (we use &lt;30 mmHg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies support the use of delta pressure to diagnose ACS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 116 patients with diaphyseal fractures of the tibia, the authors performed continuous blood pressure and compartment pressure monitoring to assess for ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/80\">",
"       80",
"      </a>",
"      ]. A delta pressure of 30 mmHg was used as the diagnostic threshold. Three patients were diagnosed with ACS immediately, one patient during the first 12 hours of treatment, and two patients during the second 12 hours. At six month follow-up, no patient had sequelae of ACS. Of note, 37 patients had isolated compartment pressure measurements over 40 mmHg during the first 24 hours.",
"     </li>",
"     <li>",
"      Another observational study evaluated 101 patients with tibial fractures using continuous compartment pressure monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/81\">",
"       81",
"      </a>",
"      ]. Although 41 patients had compartment pressures above 30 mmHg continuously for six hours, no patient whose delta pressure remained above 30 mmHg developed ACS.",
"     </li>",
"     <li>",
"      In a similar observational study of 25 consecutive patients with closed tibia fractures continuously monitored for the development of ACS, 75 percent of the patients who did not meet the criteria for fasciotomy (delta pressure of 20 mmHg) demonstrated absolute tissue pressures above 30 mmHg but none developed ACS [",
"      <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors of these studies emphasize the",
"    <strong>",
"     importance of following trends in compartment and delta pressures",
"    </strong>",
"    . When compartment pressures are trending downward, it is often safe not to intervene emergently, provided the delta pressure is also improving.",
"   </p>",
"   <p>",
"    Once a consistent trend of decreasing compartment pressures becomes apparent over a minimum of six hours of observation, monitoring may be discontinued. Conversely, a single normal compartment pressure reading, which may be performed early in the course of the disease, does",
"    <strong>",
"     not",
"    </strong>",
"    rule out ACS. Serial or continuous measurements are important when patient risk or clinical suspicion is high.",
"   </p>",
"   <p>",
"    Some surgeons continue to use absolute compartment pressure measurements to diagnose ACS. Traditional recommendations for decompression include absolute pressure readings above 30 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/64\">",
"     64",
"    </a>",
"    ] or above 45 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/1\">",
"     1",
"    </a>",
"    ]. We do not recommend this approach for the reasons alluded to above (eg, increased rate of unnecessary fasciotomies).",
"   </p>",
"   <p>",
"    Continuous invasive monitoring of alert patients who are able to convey their symptoms and who are closely observed for clinical findings of ACS is unlikely to improve outcomes. This was demonstrated in a trial of 200 consecutive patients with tibia fractures randomized to continuous invasive compartment pressure monitoring or clinical observation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/83\">",
"     83",
"    </a>",
"    ]. No cases of ACS were missed in the clinical observation group and at the six month follow-up there was no significant difference in outcome between groups. An observational study noted similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Investigational techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alternative noninvasive methods of measuring compartment pressures are under study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/53\">",
"     53",
"    </a>",
"    ]. Potential approaches include ultrasound with a pulsed phase-locked loop, laser Doppler flowmetry, and near-infrared spectroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/85\">",
"     85",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most important aspect of diagnosis is to maintain a high index of suspicion among patients at risk for acute compartment syndrome (ACS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"     4",
"    </a>",
"    ]. Serial examinations are important in such patients. Definitive diagnosis of ACS must be made by measuring compartment pressures. With early diagnosis and appropriate treatment, the complications of ACS can be prevented and normal function of the extremity maintained. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Immediate management of suspected ACS includes relieving all external pressure on the compartment. Any dressing, splint, cast, or other restrictive covering should be removed. The limb should neither be elevated nor placed in a dependent position. Placing the limb level with the heart helps to avoid reductions in arterial inflow and increases in compartment pressures from dependent swelling, both of which can exacerbate limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analgesics should be given and supplementary oxygen provided. Hypotension reduces perfusion, exacerbating tissue injury, and should be treated with boluses of intravenous isotonic saline.",
"   </p>",
"   <p>",
"    Fasciotomy to fully decompress all involved compartments is the definitive treatment for ACS in the great majority of cases (",
"    <a class=\"graphic graphic_figure graphicRef70951 graphicRef55311 \" href=\"UTD.htm?35/58/36778\">",
"     figure 4A-B",
"    </a>",
"    ). Delays in performing fasciotomy increase morbidity, including the need for amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The performance of fasciotomy procedures is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H548658810#H548658810\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fasciotomy is occasionally not indicated or may not be necessary. As an example, it should be avoided when the muscle is already dead. Fasciotomy in such instances provides no benefit and can increase the risk of infection. Definitive treatment for such injuries often involves amputation. In specific, low-risk circumstances, fasciotomy",
"    <strong>",
"     may",
"    </strong>",
"    not be necessary, but this decision must be made by the treating surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H428236833#H428236833\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperbaric oxygen has been described as adjunct treatment for ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/61,91,92\">",
"     61,91,92",
"    </a>",
"    ]. Further research is needed to determine the appropriate role of hyperbaric oxygen therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Making the diagnosis of acute compartment syndrome (ACS) in young children can be challenging. Trauma is the cause in most cases, but as in adults ACS can develop from a number of conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/26\">",
"     26",
"    </a>",
"    ]. Compartment pressures should be measured when a definitive diagnosis is needed, such as in children with a depressed level of consciousness, possible nerve injury, or those unable to cooperate and at high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 42 skeletally immature children with ACS, sustained primarily in association with leg fractures following a motor vehicle collision, reported that most patients had good outcomes despite a relatively long period between injury and fasciotomy (average 20.5 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/93\">",
"     93",
"    </a>",
"    ]. The authors emphasize the importance of vigilant monitoring in this age group following injury.",
"   </p>",
"   <p>",
"    Supracondylar fractures occur primarily in children and may be complicated by ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/57/8090/abstract/94\">",
"     94",
"    </a>",
"    ]. If an ipsilateral forearm fracture is also present, the risk of developing ACS increases. Children with supracondylar fractures should be closely monitored and compartment pressures measured if there is any doubt concerning the possibility of ACS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=see_link\">",
"     \"Evaluation and management of supracondylar fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DISEASE COURSE AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis and appropriate treatment of ACS generally produce good functional and cosmetic results. However, mortality rates in patients with ACS requiring fasciotomy may reach as high as 15 percent, and can be much higher in patients with severe trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=see_link&amp;anchor=H443286216#H443286216\">",
"     \"Patient management following extremity fasciotomy\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morbidity following fasciotomy may be significant. Skin grafts may be needed for incisions and muscle weakness can persist in the affected limb. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H548658810#H548658810\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current understanding of how long muscles can tolerate ischemia is based primarily upon extrapolations from experimental models. According to these models, muscles can tolerate up to three hours of complete warm ischemia before the onset of necrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=see_link&amp;anchor=H443276740#H443276740\">",
"     \"Lower extremity fasciotomy techniques\", section on 'Ischemia-reperfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most important determinant of a poor outcome from ACS is a delayed or missed diagnosis. ACS can result in muscle contracture, sensory deficits, paralysis, infection, fracture nonunion, and possibly limb amputation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=see_link&amp;anchor=H443283619#H443283619\">",
"     \"Patient management following extremity fasciotomy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhabdomyolysis may occur with muscle ischemia, resulting in myoglobinuria and possible renal failure necessitating dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link&amp;anchor=H11512176#H11512176\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=see_link\">",
"       \"Patient information: Rhabdomyolysis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=see_link\">",
"       \"Patient information: Acute compartment syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute compartment syndrome (ACS) occurs when increased pressure within a compartment bounded by unyielding fascial membranes compromises the circulation and function of the tissues within that space (",
"      <a class=\"graphic graphic_figure graphicRef59437 \" href=\"UTD.htm?25/33/26137\">",
"       figure 1",
"      </a>",
"      ). ACS is a surgical emergency. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ACS most often develops soon after significant trauma, particularly involving long bone fractures of the lower leg or forearm. ACS may also occur following minor trauma or from nontraumatic causes, such as ischemia-reperfusion injury, coagulopathy, certain animal envenomations and bites, extravasation of IV fluids, injection of recreational drugs, and prolonged limb compression. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The accuracy of the physical examination for diagnosing ACS is limited. Early symptoms of ACS include progressive pain out of proportion to the injury; signs include tense swollen compartments and pain with passive stretching of muscles within the affected compartment. Important clues to the development of ACS include rapid progression of symptoms and signs over a few hours and the presence of multiple findings consistent with the diagnosis in a patient at risk. Close observation and serial examinations in patients at risk for ACS are of great importance. Motor deficits are",
"      <strong>",
"       LATE",
"      </strong>",
"      findings associated with irreversible muscle and nerve damage. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compartment pressures should be measured whenever ACS is suspected based upon the patient's risk factors and clinical findings. A single normal compartment pressure reading, which may be performed early in the course of the disease, does",
"      <strong>",
"       NOT",
"      </strong>",
"      rule out ACS. Serial or continuous measurements are important when patient risk is moderate to high or clinical suspicion exists. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Measurement of compartment pressures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal pressure of a tissue compartment falls between 0 and 8 mmHg. Signs of ACS develop as tissue pressure rises and approaches systemic pressure. However, the pressure necessary for injury varies. Higher pressures may be necessary before injury occurs to peripheral nerves in patients with systemic hypertension, while ACS may develop at lower pressures in those with hypotension or peripheral vascular disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interpretation of measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest diagnosing ACS using a threshold equaling the difference between the diastolic blood pressure and the compartment pressure of 30 mmHg or less. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interpretation of measurements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate management of suspected ACS includes relieving all external pressure on the compartment. Any dressing, splint, cast, or other restrictive covering should be removed. The limb should",
"      <strong>",
"       not",
"      </strong>",
"      be elevated. Analgesics should be given and supplementary oxygen provided. Hypotension reduces perfusion and should be treated with intravenous boluses of isotonic saline. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fasciotomy to fully decompress all involved compartments is the definitive treatment for ACS in the great majority of cases. Delays in performing fasciotomy increase morbidity. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3204972\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/1\">",
"      Matsen FA 3rd, Krugmire RB Jr. Compartmental syndromes. Surg Gynecol Obstet 1978; 147:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/2\">",
"      Elliott KG, Johnstone AJ. Diagnosing acute compartment syndrome. J Bone Joint Surg Br 2003; 85:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/3\">",
"      Peters CL, Scott SM. Compartment syndrome in the forearm following fractures of the radial head or neck in children. J Bone Joint Surg Am 1995; 77:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/4\">",
"      McQueen MM, Gaston P, Court-Brown CM. Acute compartment syndrome. Who is at risk? J Bone Joint Surg Br 2000; 82:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/5\">",
"      K&ouml;stler W, Strohm PC, S&uuml;dkamp NP. Acute compartment syndrome of the limb. Injury 2005; 36:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/6\">",
"      Patel RV, Haddad FS. Compartment syndromes. Br J Hosp Med (Lond) 2005; 66:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/7\">",
"      DeLee JC, Stiehl JB. Open tibia fracture with compartment syndrome. Clin Orthop Relat Res 1981; :175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/8\">",
"      Rizvi, S, Catenacci, M. Responding promptly to acute compartment syndrome. Emerg Med 2008; 40:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/9\">",
"      Park S, Ahn J, Gee AO, et al. Compartment syndrome in tibial fractures. J Orthop Trauma 2009; 23:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/10\">",
"      Hope MJ, McQueen MM. Acute compartment syndrome in the absence of fracture. J Orthop Trauma 2004; 18:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/11\">",
"      Dresing K, Peterson T, Schmit-Neuerburg KP. Compartment pressure in the carpal tunnel in distal fractures of the radius. A prospective study. Arch Orthop Trauma Surg 1994; 113:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/12\">",
"      McQueen MM, Christie J, Court-Brown CM. Compartment pressures after intramedullary nailing of the tibia. J Bone Joint Surg Br 1990; 72:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/13\">",
"      Fuller DA, Barrett M, Marburger RK, Hirsch R. Carpal canal pressures after volar plating of distal radius fractures. J Hand Surg Br 2006; 31:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/14\">",
"      Olson SA, Glasgow RR. Acute compartment syndrome in lower extremity musculoskeletal trauma. J Am Acad Orthop Surg 2005; 13:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/15\">",
"      Beraldo S, Dodds SR. Lower limb acute compartment syndrome after colorectal surgery in prolonged lithotomy position. Dis Colon Rectum 2006; 49:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/16\">",
"      Figueras Coll G, Albort&iacute; Fit&oacute; G, Iborra Gonz&agrave;lez M, et al. Bilateral compartment syndrome in thighs and legs by methanol intoxication: a case report. Emerg Med J 2008; 25:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/17\">",
"      Morin RJ, Swan KG, Tan V. Acute forearm compartment syndrome secondary to local arterial injury after penetrating trauma. J Trauma 2009; 66:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/18\">",
"      Suzuki T, Moirmura N, Kawai K, Sugiyama M. Arterial injury associated with acute compartment syndrome of the thigh following blunt trauma. Injury 2005; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/19\">",
"      Heppenstall RB, Scott R, Sapega A, et al. A comparative study of the tolerance of skeletal muscle to ischemia. Tourniquet application compared with acute compartment syndrome. J Bone Joint Surg Am 1986; 68:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/20\">",
"      Tiwari A, Haq AI, Myint F, Hamilton G. Acute compartment syndromes. Br J Surg 2002; 89:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/21\">",
"      Modrall JG, Sadjadi J, Ali AT, et al. Deep vein harvest: predicting need for fasciotomy. J Vasc Surg 2004; 39:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/22\">",
"      Gabisan GG, Gentile DR. Acute peroneal compartment syndrome following ankle inversion injury: a case report. Am J Sports Med 2004; 32:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/23\">",
"      Kym MR, Worsing RA Jr. Compartment syndrome in the foot after an inversion injury to the ankle. A case report. J Bone Joint Surg Am 1990; 72:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/24\">",
"      Ortmann FW 4th, Carr JB. Metachronous acute compartment syndromes. Orthopedics 2006; 29:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/25\">",
"      K&ouml;stler W, Strohm PC, S&uuml;dkamp NP. Acute compartment syndrome of the limb. Injury 2004; 35:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/26\">",
"      Ramos C, Whyte CM, Harris BH. Nontraumatic compartment syndrome of the extremities in children. J Pediatr Surg 2006; 41:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/27\">",
"      Mahdi H, Gough S, Gill KK, Mahon B. Acute spontaneous compartment syndrome in recent onset type 1 diabetes. Emerg Med J 2007; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/28\">",
"      Defraigne JO, Pincemail J. Local and systemic consequences of severe ischemia and reperfusion of the skeletal muscle. Physiopathology and prevention. Acta Chir Belg 1998; 98:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/29\">",
"      Qvarfordt P, Christenson JT, Ekl&ouml;f B, Ohlin P. Intramuscular pressure after revascularization of the popliteal artery in severe ischaemia. Br J Surg 1983; 70:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/30\">",
"      Ehrendorfer S. Acute compartment syndrome of the thigh after joint replacement with anticoagulation. J Bone Joint Surg Br 1999; 81:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/31\">",
"      Shabat S, Carmel A, Cohen Y, et al. Iatrogenic forearm compartment syndrome in a cardiac intensive care unit induced by brachial artery puncture and acute anticoagulation. J Interv Cardiol 2002; 15:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/32\">",
"      Busch T, S&icirc;rbu H, Zenker D, Dalichau H. Vascular complications related to intraaortic balloon counterpulsation: an analysis of ten years experience. Thorac Cardiovasc Surg 1997; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/33\">",
"      O'Connor G, McMahon G. Complications of heroin abuse. Eur J Emerg Med 2008; 15:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/34\">",
"      Sahni V, Garg D, Garg S, et al. Unusual complications of heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. Clin Toxicol (Phila) 2008; 46:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/35\">",
"      Tavares JO. Acute compartment syndrome in osteochondromatosis. Orthopedics 2004; 27:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/36\">",
"      Kleshinski J, Bittar S, Wahlquist M, et al. Review of compartment syndrome due to group A streptococcal infection. Am J Med Sci 2008; 336:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/37\">",
"      Burnside J, Costello JM Jr, Angelastro NJ, Blankenship J. Forearm compartment syndrome following thrombolytic therapy for acute myocardial infarction. Clin Cardiol 1994; 17:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/38\">",
"      Yip TR, Demaerschalk BM. Forearm compartment syndrome following intravenous thrombolytic therapy for acute ischemic stroke. Neurocrit Care 2005; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/39\">",
"      Roberge RJ, McLane M. Compartment syndrome after simple venipuncture in an anticoagulated patient. J Emerg Med 1999; 17:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/40\">",
"      Mills J, Pretorius V, Lording T, et al. Bilateral anterior compartment syndrome after routine coronary artery bypass surgery and severe hypothyroidism. Ann Thorac Surg 2010; 90:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/41\">",
"      Kolli A, Au JT, Lee DC, et al. Compartment syndrome after endoscopic harvest of the great saphenous vein during coronary artery bypass grafting. Ann Thorac Surg 2010; 89:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/42\">",
"      Kerrary S, Schouman T, Cox A, et al. Acute compartment syndrome following fibula flap harvest for mandibular reconstruction. J Craniomaxillofac Surg 2011; 39:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/43\">",
"      Frink M, Hildebrand F, Krettek C, et al. Compartment syndrome of the lower leg and foot. Clin Orthop Relat Res 2010; 468:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/44\">",
"      BURTON AC. On the physical equilibrium of small blood vessels. Am J Physiol 1951; 164:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/45\">",
"      Whitesides TE, Haney TC, Morimoto K, Harada H. Tissue pressure measurements as a determinant for the need of fasciotomy. Clin Orthop Relat Res 1975; :43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/46\">",
"      Sheridan GW, Matsen FA 3rd, Krugmire RB Jr. Further investigations on the pathophysiology of the compartmental syndrome. Clin Orthop Relat Res 1977; :266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/47\">",
"      Brumback RJ. Traumatic rupture of the superior gluteal artery, without fracture of the pelvis, causing compartment syndrome of the buttock. A case report. J Bone Joint Surg Am 1990; 72:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/48\">",
"      Bonutti PM, Bell GR. Compartment syndrome of the foot. A case report. J Bone Joint Surg Am 1986; 68:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/49\">",
"      Greene TL, Louis DS. Compartment syndrome of the arm--a complication of the pneumatic tourniquet. A case report. J Bone Joint Surg Am 1983; 65:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/50\">",
"      Botte MJ, Gelberman RH. Acute compartment syndrome of the forearm. Hand Clin 1998; 14:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/51\">",
"      Kalyani BS, Fisher BE, Roberts CS, Giannoudis PV. Compartment syndrome of the forearm: a systematic review. J Hand Surg Am 2011; 36:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/52\">",
"      Mith&ouml;fer K, Lhowe DW, Vrahas MS, et al. Clinical spectrum of acute compartment syndrome of the thigh and its relation to associated injuries. Clin Orthop Relat Res 2004; :223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/53\">",
"      Shadgan B, Menon M, O'Brien PJ, Reid WD. Diagnostic techniques in acute compartment syndrome of the leg. J Orthop Trauma 2008; 22:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/54\">",
"      Myers RA. Hyperbaric oxygen therapy for trauma: crush injury, compartment syndrome, and other acute traumatic peripheral ischemias. Int Anesthesiol Clin 2000; 38:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/55\">",
"      Newton EJ, Love J. Acute complications of extremity trauma. Emerg Med Clin North Am 2007; 25:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/56\">",
"      Ulmer T. The clinical diagnosis of compartment syndrome of the lower leg: are clinical findings predictive of the disorder? J Orthop Trauma 2002; 16:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/57\">",
"      Shuler FD, Dietz MJ. Physicians' ability to manually detect isolated elevations in leg intracompartmental pressure. J Bone Joint Surg Am 2010; 92:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/58\">",
"      Mubarak SJ, Owen CA, Hargens AR, et al. Acute compartment syndromes: diagnosis and treatment with the aid of the wick catheter. J Bone Joint Surg Am 1978; 60:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/59\">",
"      Tiwari A, Myint F, Hamilton G. Compartment syndrome. Eur J Vasc Endovasc Surg 2002; 24:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/60\">",
"      Mars M, Hadley GP. Failure of pulse oximetry in the assessment of raised limb intracompartmental pressure. Injury 1994; 25:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/61\">",
"      Wattel F, Mathieu D, Nevi&egrave;re R, Bocquillon N. Acute peripheral ischaemia and compartment syndromes: a role for hyperbaric oxygenation. Anaesthesia 1998; 53 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/62\">",
"      Kosir R, Moore FA, Selby JH, et al. Acute lower extremity compartment syndrome (ALECS) screening protocol in critically ill trauma patients. J Trauma 2007; 63:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/63\">",
"      Wall CJ, Richardson MD, Lowe AJ, et al. Survey of management of acute, traumatic compartment syndrome of the leg in Australia. ANZ J Surg 2007; 77:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/64\">",
"      Mubarak SJ, Owen CA. Double-incision fasciotomy of the leg for decompression in compartment syndromes. J Bone Joint Surg Am 1977; 59:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/65\">",
"      Rorabeck CH, Castle GS, Hardie R, Logan J. Compartmental pressure measurements: an experimental investigation using the slit catheter. J Trauma 1981; 21:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/66\">",
"      Willy C, Gerngross H, Sterk J. Measurement of intracompartmental pressure with use of a new electronic transducer-tipped catheter system. J Bone Joint Surg Am 1999; 81:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/67\">",
"      Uliasz A, Ishida JT, Fleming JK, Yamamoto LG. Comparing the methods of measuring compartment pressures in acute compartment syndrome. Am J Emerg Med 2003; 21:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/68\">",
"      Allen MJ, Stirling AJ, Crawshaw CV, Barnes MR. Intracompartmental pressure monitoring of leg injuries. An aid to management. J Bone Joint Surg Br 1985; 67:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/69\">",
"      Collinge C, Kuper M. Comparison of three methods for measuring intracompartmental pressure in injured limbs of trauma patients. J Orthop Trauma 2010; 24:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/70\">",
"      Hammerberg EM, Whitesides TE Jr, Seiler JG 3rd. The reliability of measurement of tissue pressure in compartment syndrome. J Orthop Trauma 2012; 26:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/71\">",
"      Heckman MM, Whitesides TE Jr, Grewe SR, Rooks MD. Compartment pressure in association with closed tibial fractures. The relationship between tissue pressure, compartment, and the distance from the site of the fracture. J Bone Joint Surg Am 1994; 76:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/72\">",
"      Klenerman L. The evolution of the compartment syndrome since 1948 as recorded in the JBJS (B). J Bone Joint Surg Br 2007; 89:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/73\">",
"      Reneman RS, Slaaf DW, Lindbom L, et al. Muscle blood flow disturbances produced by simultaneously elevated venous and total muscle tissue pressure. Microvasc Res 1980; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/74\">",
"      Wiederhielm CA, Weston BV. Microvascular, lymphatic, and tissue pressures in the unanesthetized mammal. Am J Physiol 1973; 225:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/75\">",
"      Dahn I, Lassen NA, Westling H. Blood flow in human muscles during external pressure or venous stasis. Clin Sci 1967; 32:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/76\">",
"      Szabo RM, Gelberman RH, Williamson RV, Hargens AR. Effects of increased systemic blood pressure on the tissue fluid pressure threshold of peripheral nerve. J Orthop Res 1983; 1:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/77\">",
"      Zweifach SS, Hargens AR, Evans KL, et al. Skeletal muscle necrosis in pressurized compartments associated with hemorrhagic hypotension. J Trauma 1980; 20:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/78\">",
"      Heppenstall RB, Sapega AA, Scott R, et al. The compartment syndrome. An experimental and clinical study of muscular energy metabolism using phosphorus nuclear magnetic resonance spectroscopy. Clin Orthop Relat Res 1988; :138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/79\">",
"      Rorabeck CH. The treatment of compartment syndromes of the leg. J Bone Joint Surg Br 1984; 66:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/80\">",
"      McQueen MM, Court-Brown CM. Compartment monitoring in tibial fractures. The pressure threshold for decompression. J Bone Joint Surg Br 1996; 78:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/81\">",
"      White TO, Howell GE, Will EM, et al. Elevated intramuscular compartment pressures do not influence outcome after tibial fracture. J Trauma 2003; 55:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/82\">",
"      Ovre S, Hvaal K, Holm I, et al. Compartment pressure in nailed tibial fractures. A threshold of 30 mmHg for decompression gives 29% fasciotomies. Arch Orthop Trauma Surg 1998; 118:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/83\">",
"      Harris IA, Kadir A, Donald G. Continuous compartment pressure monitoring for tibia fractures: does it influence outcome? J Trauma 2006; 60:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/84\">",
"      Al-Dadah OQ, Darrah C, Cooper A, et al. Continuous compartment pressure monitoring vs. clinical monitoring in tibial diaphyseal fractures. Injury 2008; 39:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/85\">",
"      Shuler MS, Reisman WM, Whitesides TE Jr, et al. Near-infrared spectroscopy in lower extremity trauma. J Bone Joint Surg Am 2009; 91:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/86\">",
"      Styf J, Wiger P. Abnormally increased intramuscular pressure in human legs: comparison of two experimental models. J Trauma 1998; 45:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/87\">",
"      Sheridan GW, Matsen FA 3rd. Fasciotomy in the treatment of the acute compartment syndrome. J Bone Joint Surg Am 1976; 58:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/88\">",
"      Finkelstein JA, Hunter GA, Hu RW. Lower limb compartment syndrome: course after delayed fasciotomy. J Trauma 1996; 40:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/89\">",
"      Riede U, Schmid MR, Romero J. Conservative treatment of an acute compartment syndrome of the thigh. Arch Orthop Trauma Surg 2007; 127:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/90\">",
"      Robinson D, On E, Halperin N. Anterior compartment syndrome of the thigh in athletes--indications for conservative treatment. J Trauma 1992; 32:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/91\">",
"      Strauss MB, Hargens AR, Gershuni DH, et al. Delayed use of hyperbaric oxygen for treatment of a model anterior compartment syndrome. J Orthop Res 1986; 4:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/92\">",
"      Tibbles PM, Edelsberg JS. Hyperbaric-oxygen therapy. N Engl J Med 1996; 334:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/93\">",
"      Flynn JM, Bashyal RK, Yeger-McKeever M, et al. Acute traumatic compartment syndrome of the leg in children: diagnosis and outcome. J Bone Joint Surg Am 2011; 93:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/57/8090/abstract/94\">",
"      Omid R, Choi PD, Skaggs DL. Supracondylar humeral fractures in children. J Bone Joint Surg Am 2008; 90:1121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 358 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8090=[""].join("\n");
var outline_f7_57_8090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Long bone fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trauma without fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nontraumatic causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANATOMIC COMPARTMENTS AND RELATED CLINICAL SIGNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEASUREMENT OF COMPARTMENT PRESSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Direct measurement techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interpretation of measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Investigational techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DISEASE COURSE AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3204972\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/358\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/358|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/33/26137\" title=\"figure 1\">",
"      Cross section of the leg and forearm compartments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/27/42424\" title=\"figure 2\">",
"      Muscle compartments of the leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/14/36071\" title=\"figure 3\">",
"      Muscle compartments of the thigh",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/54/11112\" title=\"figure 4A\">",
"      Two incision leg fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/48/29448\" title=\"figure 4B\">",
"      Single incision fasciotomy lower leg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35305?source=related_link\">",
"      Approach to the diagnosis and therapy of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28215?source=related_link\">",
"      Chronic exertional compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/13/21722?source=related_link\">",
"      Distal radius fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/22/25961?source=related_link\">",
"      Evaluation and management of supracondylar fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35897?source=related_link\">",
"      Lower extremity fasciotomy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26358?source=related_link\">",
"      Overview of tibial fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/9/32913?source=related_link\">",
"      Patient information: Acute compartment syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3400?source=related_link\">",
"      Patient management following extremity fasciotomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_57_8091="Risks for common diseases";
var content_f7_57_8091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risks for common diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Average risk",
"      </td>",
"      <td class=\"subtitle1\">",
"       Moderate risk",
"      </td>",
"      <td class=\"subtitle1\">",
"       High risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        &bull; No known family history,",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        &bull; Only one second or more distantly related relative",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        &bull; One first degree relative (FDR) with onset of disease at an average age,",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        &bull; Two second degree relatives (SDR) on the same side of the family*",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        &bull; Premature disease or unusual presentation in an FDR",
"       </p>",
"       <p>",
"        &bull; 2 &ge; affected FDRs*",
"       </p>",
"       <p>",
"        &bull; 2 &ge; SDRs, with at least one having premature onset*",
"       </p>",
"       <p>",
"        &bull; 3 &ge; affected relatives*",
"       </p>",
"       <p>",
"        &bull; Moderate risk status on both sides of the family",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Relatives must be on the same side of the family.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8091=[""].join("\n");
var outline_f7_57_8091=null;
var title_f7_57_8092="Initial blood lead testing of neonates";
var content_f7_57_8092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial blood lead testing of neonates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Initial venous blood lead level* (BLL; &micro;g/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perform follow-up test(s)",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;5",
"       </td>",
"       <td>",
"        According to local lead screening guidelines for children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-24",
"       </td>",
"       <td>",
"        Within 1 month (at first newborn visit).&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-44",
"       </td>",
"       <td>",
"        Within 2 weeks. Consultation with a clinician experienced in the management of children with BLLs in this range is strongly advised.&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;45",
"       </td>",
"       <td>",
"        Within 24 hours and then at frequent intervals depending on clinical interventions and trend in BLLs. Prompt consultation with a clinician experienced in the management of children withd BLLs in this range is strongly advised.&loz;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The initial blood lead level may be either from an umbilical cord sample at the time of delivery or an infant venous BLL. A venous blood sample is preferred over a capillary sample. Decisions to initiate or stop breastfeeding or initiate chelation therapy should be based on venous blood lead test results only.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      If infants are breastfeeding, also follow recommendations in Chapter 9.",
"      <br>",
"       &Delta; According to pediatric health supervision guidelines (well-baby visit schedule) or as clinically indicated based on trends in blood lead levels.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        The higher the BLL on the initial test, the more urgent the need for confirmatory testing.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ettinger AS, Gurthrie Wengrovitz A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010. Available at",
"     <a href=\"file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\">",
"      file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8092=[""].join("\n");
var outline_f7_57_8092=null;
var title_f7_57_8093="Fat soluble vitamin supplements for biliary atresia";
var content_f7_57_8093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fat soluble vitamin deficiencies and supplementation for patients with biliary atresia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Fat-soluble vitamin",
"       </td>",
"       <td class=\"subtitle1\">",
"        How to monitor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Standard oral treatment recommendation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs and symptoms of deficiency",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended supplementation in setting of deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin A",
"       </td>",
"       <td>",
"        <p>",
"         Measure serum or plasma Retinol and Retinol Binding Protein (RBP)",
"        </p>",
"        <p>",
"         Interpretation: Normal range for retinol 19 to 77 &micro;g/dL; Retinol:RBP &lt;0.8 mol/mol defines deficiency when Retinol &lt;20 &micro;g/dL",
"        </p>",
"       </td>",
"       <td>",
"        Liquid vitamin A, 3000 IU/day",
"       </td>",
"       <td>",
"        <p>",
"         Keratinization of the skin and mucous membranes; ocular effects such as xerophthalmia, night blindness, xerosis, and bitot spots",
"        </p>",
"        <p>",
"         Retinol:RBP molar ratio &lt;0.8 and serum retinol &lt;20 &micro;g/dL",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Liquid vitamin A 5000 IU/day by mouth; recheck levels in&nbsp;one month",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         25,000 to 50,000 IU/day by mouth for&nbsp;one to&nbsp;four&nbsp;weeks; recheck levels weekly",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         50,000 IU IM once/month up to&nbsp;two months; recheck levels monthly",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vitamin D",
"       </td>",
"       <td>",
"        <p>",
"         Measure serum 25-OH-D",
"        </p>",
"        <p>",
"         Interpretation: Optimal levels &gt;30 ng/ml",
"        </p>",
"       </td>",
"       <td>",
"        Cholecalciferol or ergocalciferol, 800 IU/d",
"       </td>",
"       <td>",
"        <p>",
"         Rickets; fractures; osteomalacia",
"        </p>",
"        <p>",
"         25-OH-D &lt;15 ng/mL",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Cholecalciferol or ergocalciferol 1200 to 4000 IU/day by mouth; recheck levels in&nbsp;one month",
"        </p>",
"        <p>",
"         If child remains deficient, give 4000 to 8000 IU/day; recheck levels in one month",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Give 1,25 OH",
"         <sub>",
"          2",
"         </sub>",
"         D, 0.05 to 0.2 &micro;g/kg/day; recheck serum 1,25 OH",
"         <sub>",
"          2",
"         </sub>",
"         D levels in&nbsp;one month",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vitamin E",
"       </td>",
"       <td>",
"        <p>",
"         Measure serum vitamin E and total lipids",
"        </p>",
"        <p>",
"         Interpretation: Normal vitamin E:total lipid ratio &gt;0.6 mg/g (age &lt;1 year) or &gt;0.8 mg/g (age &gt;1 year)",
"        </p>",
"       </td>",
"       <td>",
"        25 IU/kg/day of TPGS",
"       </td>",
"       <td>",
"        <p>",
"         Peripheral neuropathy, ataxia; ophthalmoplegia",
"        </p>",
"        <p>",
"         Vit. E:total lipid ratio: &lt;0.6 mg/g (age &lt;1 year) or &lt;0.8 mg/g (age &gt;1 year) is deficient",
"        </p>",
"       </td>",
"       <td>",
"        If deficient, 50 IU/kg/day of TPGS - recheck levels in&nbsp;one month",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vitamin K",
"       </td>",
"       <td>",
"        Measure PT, INR, and PIVKA-II",
"       </td>",
"       <td>",
"        Vitamin K",
"        <sub>",
"         1",
"        </sub>",
"        , 2.5 mg twice weekly, or up to 5.0 mg daily",
"       </td>",
"       <td>",
"        Prolonged prothrombin time, increased INR (INR &gt;1.2); elevated PIVKA-II; coagulopathy; bruising; bleeding",
"       </td>",
"       <td>",
"        If INR &gt;1.5 and &le;1.8: give 5 mg vitamin K",
"        <sub>",
"         1",
"        </sub>",
"        daily by mouth and/or 2 to 5 mg vitamin K intramuscularly one time; recheck PT/INR in&nbsp;one to&nbsp;two&nbsp;days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IU: international units; 25-OH-D: 25-hydroxyvitamin D; 1,25-OH",
"     <sub>",
"      2",
"     </sub>",
"     D: 1,25 dihydroxyvitamin D; TPGS: Tocopherol polyethylene glycol succinate (water miscible form of vitamin E); PT: prothrombin time; INR: international normalized ratio; PIVKA-II: protein induced by vitamin K absence II; Vitamin K",
"     <sub>",
"      1",
"     </sub>",
"     : phytonadione.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8093=[""].join("\n");
var outline_f7_57_8093=null;
var title_f7_57_8094="AVID subset analysis";
var content_f7_57_8094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    ICD reduces mortality in survivors of sudden death",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 392px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subset analysis of 1016 survivors of sudden death or hemodynamically significant ventricular tachycardia entered into the AVID trial. The hazard ratios for death from any cause with the implantable cardioverter defibrillator (ICD), compared with amiodarone, were not significantly different for any of the prespecified subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators, N Engl J Med 1997; 337:1576.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8094=[""].join("\n");
var outline_f7_57_8094=null;
var title_f7_57_8095="Rochester Ochsner forceps";
var content_f7_57_8095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rochester-Ochsner forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 235px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AOsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poorG1/X00i5sbRLG81C9vS/k29r5YYhACxLSOigAEHrk9gaANmiuZXxFq5KZ8Ga4oON2biy+X/yYpW8Qav5ZKeDtZLdlNxZjP8A5HoA6WiuYXxDrZRi3gzVlcYwPtVng/j51L/wkGs5wfB2rfX7VZ4/9HUAdNRWB/bmpHp4V1f8ZrQf+16ZL4g1ONMjwhrkp/uxzWX/ALNcD/JoA6KiuYl8S6sjAL4I8QyDGcrPYAfTm5rV8Oaxba/olpqdksiQ3CZ2SgB42BIZGAJG5WBU4JGQeTQBpUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcR4nmkX4qeB4l2+U9vqJbPqEhxj8z/nFdvXFeKjt+JXgb5GYt9vXK9F/cqcn24x9SKAO1ooooAK5/QPFum65Jpq2Xm7dRsTqNqz7cSwgoCcAkggyJkED73qDjnPi1/ZN22kad4k8RxaJosjtcXKyTxwreeW0eLdmYjKsGbKjrt9q8xfw94LfUpNS03xppllq8MT/2FPZ30SNDOZZJWWIBgkkTNKyFGHdwAN2SAfSNFVNIuXvdKsrqVBHJPAkrIOillBI/WrdABXKfC/P/AAiCBtuRfXwypyCBdzAGurrl/huiReGZIo2LLFqWox5OOdt7OD0+lAHUUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcV4nf/AIud4IjycGLUHwD6Rxjp/wAC/wA9u1rhPFUgHxZ8BRbfmaDUn3Y6AJCMZ/4EPyoA7uiiigDwf9o14JPFHhSGa68MwiO3vJCniIyC2fJhAKlAcSDB2kjHJ78Hj57F2vdK8z/hEHjtdYsh/okVx9oika5i3Km+JRuI52lhnLHHNdH+0Je2a/ETQbS+m02Ff7PkkX7fppv1my5yqJ5Muxht3btvQEGuKgvrFtS0YQXOhNMdTsiTDoTW7k/aIx8rmxj2sQT83mLjp3oA+rtGCrpFiqMXQQRgMV2kjaOcdvpVys/w6zt4f0xpUMchtYiyEY2nYMitCgArk/hic+GLg5BJ1fVSSPX+0LjPYV1lcx8Ond9AuzJnd/a+qAZ9Bf3AH6AUAdPRRRQAUUUUAFFFFABXm3xx8TXXhXQbXUVjabSrdzNqcEc7wSzQErCFjkUZVhJPE+MrkIRuAJB9JrxL9qZPN8EXqPMsMLWBV2OSFzf2HzEAZ4GaANDTNLfW/DngW6uta1+C21qFmFva6pLAbdpo3u1IkU75NioYQrkrtwQFI+bovgfq9xrvwv0e+vLi6uZGa4hWa7wZ2jjuJI4/MI6vsRdx7nJPJrN8ETmLwR8I4RGziW3gBYn7gGnSnP07fjUP7MDBvgZ4ZKqFH+k8D/r5loA9TooooAKKKKACiiigAooooAKKKKACuB8WcfF7wAc8fZtTGMn+5Cf6V31ef+M1kPxW8BtCYxKLfUwhcZAJiixkdSOOaAPQKKKKAPA/jTcxr8UrGBtcTSc6VGzrNYRXcdynnyEr++/dxsNuQ2CTn2rl7maFZtCa38RW0t6upWilYtLs0iuCLmHH+r5jIJJzyeAMmtX4y6neaV8V5rmPVNZ06KTT4Y1ayiDRzBGZirH7RCcgy8ct988CucTxW93eaZDLr/iNxNqFoI0lQsHYXEZC7ft8m7PAICMcHOKAPqHw5cR3fh7S7iFt0U1rFIhxjIKAg1o1i+CPL/4QvQPJffF/Z9vsbpuHlrg1tUAFc38P5BJoV0w6DVtTXrnpfTj+ldJXL/DmNovD92rgAnWNVbgg8HULgj9CKAOoooooAKKKKACiiigArxL9puJ5fBevNFB50iWNqioMksWv4MKAOednbmvba8K/aT1F7fwv4uVdji2tNHmCMMgk3sxIOOcHy14PHFAHR+D7eGT4e+AzLIQYPDBnVd2Af9GhQk9jgSH86Z+y5/yQnwz/ANvX/pVLVLS7z7D8LPDd4jsHtfAs82wOUBxBbEHdkYxt68YzV/8AZfXb8C/DAzni5P53MtAHqdFFFABRRRQAUUUUAFFFFABRRRQAVw3itlHxS8Bqc7zHqOOeP9Uma7muR8RDPxF8HnaOIr75s8j5I+P8+lAHXUUUUAfP3i8Tn4yeJBbr4gbfa2oMmhyyboyqEhJ1ibcM5ymQc/Pjoao3b30eo6XEZviBDcTXNskclybny2zPHuRw7AbTuIY4b5TnB+7Wf8S7KO++NPiBksvFV3PBFbCR9HG5IYzCNisogmJJbf128FvvZxWOmgXUniDTmt/D/jd4Wvrcl54njIRJkbc4FggHAJ4lGO5HSgD6a8Bwy2/gbw7DcQvBNHp1sjxOCGjYRKCpB7g8Vu1g+AY/J8C+HYcg+Xp1vHlenEajj24reoAK5n4dyiXQbwqMbdX1RSN2eRfzj/6+PeumrlPhpIH0C/woULrWqrgH/p/n5oA6uiiigAooooAKKKKACvmj9prUM2Hj23Cgn7Lolvn0/f3cmT/Lt/j9L18xfH+wj/sr4hajLKvlSa3pVo8bRf8APO1RySy/MQROBgdNpxyeQDpDPHJ8HhAciW2+G+/O4YIlt8dPrD+tdT+zKuz4G+FxnPyTnrnrcSGuSuokj+AupXSTeVM/gPTYWLqSu0RTHaPdt5H5V2f7N6ovwS8LCMgr5Eh49fNfP65oA9KooooAKKKKACiiigAooooAKKKKACuR8Rhj8RfB21gFEd8zA55+SMcfnXXVyPiRQfiF4ObPKre8ev7taAOuooooA+YPHmn3+p/GTxpINA1HVbWA2MKPabcIRbh9pzbTd3/2cA9+zbrRHfVtGkt/CWuyiG8t2disaMoE8bcH7Gp2jaxJDpwrc9am8UQWF58SPGV5e6bbSiXUo7X7RJrSWTHyra3BTY8iAqN2QwBOWAJxVC80jRWvrWaHStPmukuIPKkfxDCW/wBcrAKPtR5+8cbTnt1xQB9F+AF2+CdCGMYs4vx+Ucn3rfrB8CSGXwjpbtj/AFOBj0BIH6Ct6gArlvhshTw/eAnOdZ1UjjGM6hcV1Ncp8NmDaHqBRGSMa1qgUFgx/wCP6bceg6tuOO2cZNAHV0UUUAFFFFABRRRQAd8183/Fy7j1Tw54mhjNxF9r8b21nE8cReTdHZwBii5G45ifAyMnAr6Qr5a+J4e4+H10CjGa6+Ic8cAOQAytKikHd0ynJ46kcfeoA6DU7kJ+zBq8zyhhHoOnWgVXzsza25AI7HM2cehHrXb/ALM7s/wP8LmQ5PlzDrngTyAfpivOtRl2/shanqKuqLe2Vmo29RsW2tSGI6kmE/gQD0Neg/sw/wDJDPDHIPy3HQ5/5eZaAPUqKKKACiiigAooooAKKKKACiiigArmdd/5Hfwtx/Ddnp/0zWumrm9aWRvHHhrayiNYrtmB6n5YwMe/P86AOkooooA+UNRuLt/Gfi69sH0yIS65cxNJJq0lnMfJ8uPayre2+QCGIOG6scjgGOZdQkvbdXg8PXsU1zGZN+vuFdS6cvnU3Lcg4XY4yBwc4q7p6oniPxgdQg8OzyLr98YvttrctMkbS5VWaKNgVI3soJyCxPQ4p/iWHTDaRuNP8JW5nZZIi9teETKJQMAm3UZ6ruJxk88ZoA+g/ABJ8Iabk5wjDOMdGIroKwfA0jy+GbZ5CSxkmznr/rXreoAK5P4ZqF8P33TJ1rVif/Bhcf0xXWVzvgaPytKvkL7/APiaX7bsY+9dStjqemcfh26UAdFRRRQAUUUY/WgAooooAK+aviRtT4XaPqNpJJbNJ45urll3BnYm5u0KqBt3ZHUZ+7nk4r6Vr5X+Il/Lb/s/+EtQlW6Zh4luZgFl8iRkL3xU7yDgFSCTjkH3zQBs+MbNbD9iu2hjTYrafYzEH1kuInJ/Etn8a9J/Z2jSL4K+FVjUKptmYgepkck/iSTXE/GiCXRv2UbbTLoKk8en6baurnY25GhyApHJ+U8cY59K7n9nwY+DHhT/AK9M/wDj7UAeh0UUUAFFFFABRRRQAUUUUAFFFFABXL63dxQ+PvC9s7kTXEF7sUdwoiJJ9hx+JFdRXN6zGW8ceG5N52pDefJgEEkR4PqCORx6mgDpKKKKAPkbX4IbrWtWVbrQ03a5qNupu9A851nN3I2wytZ3AlJBG1QyEDHB6ByaTNYXlncSQaJa+TLG8sjeHcAAMu4jGkxlTk8fvFxn7wxkPstatBf66uoeIljkbVLwFBpFtM8AM7llDSRkvlSP4sc7eMGpdd8R6ebKaPT9ZgQSmKPzjodvvVi4HyokbZ9Bz37YBoA+kPAvHhmAYxiWfjOf+Wz1v1i+D0WPQkRBhVnuF6+kz/5x2raoAK5vwG7PpeoFyCw1a/GQwPAupMcj2wPbp1rpK5f4eMzaTqW9NjDWNRGOen2uXB6nqMH8e3QAHUUUUUAFFFFABRRRQAV8lW+n3/xf8AeE/BHg6BItB0UW76nrlyWCi4ERDpEhALAeY+BwTxnYu1n+ta88+AqWkPww0WOxVYbZxK0EIZvuCQqWAbnk/Mfd/egDh/2wtTgg+H0emyoWmuiZomwuFMcsIJyec4kIwMd/TB9B+BZY/B/wju25/s+P7o4xjj8a8Y/aXjtJPi94be+hgeK10a7usXD+bG7RRzSxhoSCCN6DOc7/ALpGAM++/DiFIPA2jJHs2GAOAiKiDcS2FVeFUZwAOAMAUAdJRRRQAUUUUAFFFFABRRRQAUUUUAFc9qzSDxr4fVQPLNvdlmOev7rA9PU/h+XQ1z2rEjxl4e44MV1z74j/APr0AdDRRRQB8neD/FN2+hIf7ZaweW6upFto7eHEG64lPlh3u4mYZOclRnJBz2uapruqrplxDN4uuo4zHyr2toCADxtX7efcYCt7DPFYvhK7ubTwrpYe/wDHMkS2sZUWSzQpyBxGi3sYKDOAVjGQCeeTU2q6vdNot9LDqfxGiMUQBeXz8BgcYw18QScjI2t9OooA+nvBy7ND2/JxdXX3M4/4+JPXmtuszw4gj0+RR0+13R6Y/wCW8ladABXLfDsltK1QlAgOs6hjAODi6kGefpXU1y3w8Kf2XqgjUKo1jUMgPv5+1SZPtk5OO2cc9aAOpooooAKKKKACiiigArzDwDaCz8OeBooGd1g0y3ZShL7i6r5hKZ+XaJF554lzj5BXoOvXp03QtRvl25tbaSYbhkfKpPP5Vxen2J0bVNHtpIUEy2FqjXhlVfPkjVow2CvHLiNjtyRcJjGzgA+bvj3rJ1D4v3ShbmFrXTNRt8SA/MohuFyoLHAOGH3V4G7ndmvsDw1JBLottJaTSTQvuYO6bTyxyMexyPoOp618ifFa2s4vjLeW1sip5Xh3UV8pCpWMLY3BUcdCACCMYGOCQa+qPhfPJdfDbwpcztvmm0q1ldsAZZolJ4HTk0AdNRRRQAUUUUAFFFFABRRRQAUUUUAFcjrq5+JfhNuOLTUOwz/yw79R+FddXI69j/hZPhIkjP2W/A/KCgDrqr6jObbT7qdSoMUTOC3TgE81YrH8ZlB4P10ysqx/YJ9xY8AeW2c0AfOXgR9UHhDQIIbP4keWlnCyNBKVhkDRjhCsTDyu68gjIBJ6Cxrupa6dO1CI6P8AEjZ5DqGaVigBBGTm2GemSM49SAc1zvh3wvHfaFptz/wjHiuaGa1im80COUsGjyGVvsR3DkEHceo9MA13wotnplzjwf4nl8tWIcRKSMIwDgjTxgjg5JXBxzxmgD6m8Io6aMyyAq32u6JBAB/4+JOuOM/StmsbwkyNpD+WzsovLtcvnORcSA5z7g1s0AFcn8N126brHBGdb1A88/8ALy9dZXK/DuRX0/WFXqms36n6/aHP8iKAOqooooAKKKKACiiigDnviFL5XgbXQG2vLZyQI20th5FKLwOerCpfFek22o20NxcmBRaMXdpziNoTxKr8jjaNwzwHRGOdtReOIBd6VZWpYqZdTsWHuEuY5SD7FY2H41lfFD4gW3gSy00fYLnVNW1S5Fpp9jAwUzSnplzwq5KjOCcsODzgA+YvFMck/wAZvFsTv9qNh4YvnacSqwZn092aT5QFJJlOdoAySQFGAPrnwVp76T4O0LTpZkmktLGCBpI1Cq5WNQSoHAHHA9K+b/jt4e1rw/4LufG/iC+sovGOqONLnTTIVjtltZIXR4juBaVio5djkYULgLk/RXw9vzqngLw3fuAHutNtpmAxgFolJHAHc+lAHQUUUUAFFFFABRRRQAUUUUAFFFFABXJ69x8RfCfBObe+H04irrK4/wAQk/8ACy/B4wcfZtQ57fdhoA7Cuf8AiErN4B8SqgUudMuQN/TPlN15HH410Fcz8T4/O+GviyLzEi8zSbtPMc4VMwsMk9gOpNAHzH4U0XSG0Kxku/h7pc7/AGOIiX+2IN0r+WvLKU+XJ+bkkjJByRTtf0Wxi0rUDB8N9GiDW0iGb+17fcnynLIMcMPz4rTsIvCtnaQWvn6LmzQIXtvEStG4CgZRv7SjOCeQWjTg42rUGrjRr3T7m1sLjSrq6uIGhWOTxCCrFlIwc6s3y57bTj0PcA+m/CVwtzpMzqMBb69jxjHK3Uqn+VbNc18O5I5vC6SwTR3EEl3ePFLHJ5iyRm5lKMH/AIgVIO7v1710tABXM+Av+PDVeD/yF77r/wBd3rpq5X4eZOn6wxzg6zf4ypB4uHHIP04PcYPegDqqKKKACiiigAooooAxfEG1tS8PRNgh78kgnH3beZh9eQOPx7V89fti6u+leJ/h5dRrIGsZprwMOhKvAQB2yNn6ivftSjuJvHWhgSMLKGyvJpEB4Mu6BIyR/uvN+deLfEW2h8XftU+ENCu4kvdL0ywa5ubeSPciPiR8sO4OIBg5HTg8ggG7+1LpL6p8P9U8sSXLRWq30cJ5WEwzIGlXHIPlzyBs5BAHAxmut+AF79v+DXhObJO2zEHIx/q2Mf8A7LWR4xsTqXww0u1tBHbRXGmXGmSiW5z5Km0kwDJt3NiWGIHA5GSQQMVX/ZQvftfwT0eIqQbWa4gJJzu/es/8nx+FAHr9FFFABRRRQAUUUUAFFFFABRRRQAVyWvlf+Fi+EgfveRfEf98xV1tcj4i/5KH4PP8A0zvf/RaUAddXM/FCJp/hn4thQZeTSLtB9TC4rpqCMjB6UAfMX7Pnw7t9C13XNJ1M/bbq80eKS5SeyAS1k8512HcSJFLR7lYcMFyQOMxfH/4aaJ/a/gvRND0y0sLrUTqHz2FokZldIVaNTtHI3BR36sepNdb8bvM+FtvovirwHbeXqctyujNYMXktZoHSSRUEWfk2OmUEZUDcwwQcVoeABefEHULS98fWlqdQstPivLMWQntPs4uHmSWNsSkSqRBGcnjkgd6AOu+CUE1r8KfDVtcFGkhtfK3J91wrEBlOBlSACD3BB7129NjjSKNI4kVI0AVVUYCgdABTqACua8BuXsdWBIO3Vr1chSP+W7evX049K6WuY+H7o+mamEO7bq9+rE9c/aZOvH5e2KAOnooooAKKKKACiiigDDs50n8Z6pEqkm2srYFivALvMSoPXoqEjpyK8e+B97D4s+OHxP8AE5+ZrVotMtWSQshg3MpIz/e+zo3sWNep6jq6aXonjLV0wVsBLNuBznyrZCe/Ygjt0/GvOf2PtJNh8Jft8igvql9NcB8DcVXEQBPX70bdfU+tAHaXCpeeD7y1tbloZU1iS28xckws94VHA/2ZBweMHniuB/Yxd2+FWoRyFsw6vNHtYY2/uoTj8ya7XWrF10r4lW1mAt3M39oQjGBu+yRKv5vA2fx/Hz/9iicH4c61bfxx6q0h+jQxAf8AoJoA+haKKKACiggHrzRQAUUUUAFFFFABRRRQAVxXjKLV4vGXhjU9M0e51SytIrxbhLaWFHRnWMRn966Ajh84JxXa0UAcxD4k1d5Cj+CtfjAz85nsSp57Yuc9Papk1/UyH3eEtbXBwP31mdw9f+PiuhooA8e+Kum+I/GM3hX7D4V1SKDTdR/tC4We8tozlFITbsnzuy2chlwAeQTWj4at9a8P+JLqdPCeqT6fJYxWsTRSWSMhSaeTBXz1ULiZfu9weAACfUKKAMBNd1JlyfCmsr7NNZ5/Sc1X/wCEk1XJH/CE+Ifr51h/8k109FAHNHxHqg2/8UZ4gOWwf31j8o9T/pPT6c0z4d2V9ZaJdtqlnJZXF1qV7di3kdHeNJLh2QMUZlztKkgE4ziuoooAKKKKACiiigAooqC+uorKyuLu4bbDBG0rt6KoyT+QoA8Z+M98+l/s8eJLiGVUk1C4kKMnG+Oe8JxkHnMTY9x+Vd98H9LTRvhb4VskhMDJp0LyRnqJHQPJn/gbNXj/AO0IpvfBPww8G4aK41i+tYyBlQAqLGQf+BTqefSvo+gDmfIkT4h3XnqJLLUdIjQIwBUNBNJvyPcXK/8AfNeDfsRtLDF42sZW/wCPea1JUMGUMfOBII4P3Bz7Cvftana08XeG2yvl3X2myIOcljGJhjHHSBuT/WvF/wBntTpPxt+LGkFVjEl59oRADwgmkK8/7sooA+iaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfGlut74U1SxcsBfQNZZUZIM37sH/wAfrarG8SiWUaXbQlQZ7+EsWHG2PMx/H91j8aAPIvHbprf7UfgPSHQzW2k2Ut+ycFY3ZZMNg9CGjhPfqOmOfdq8F+GYHiP9pn4i68JMwaTBHpaRsd21vlUkHsMwScf7de9UAYPiuBS+iXjbg1nqUTqQe8gaDnnpiY+teT+ErOXTv2ufGC/dt7/REu1UAc4Numf++g/516x46uEsvC15fyjMViY72QZx8sMiyN+iGvNdfuX0/wDav8MnY3l6n4elswytgZR5ZTkdx8o/Ej0oA9oooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArE1AzS+LNGgV1FtFBcXUg/iLjy40/DEsn5CtuvMvijrEdl4b+Id4kqg2eiraK/wDzznkWUhfr+9hOPcfgAc9+y3BHe6X4x8ULud9c12eVZWTYZIlOVOOg+aSTgdK9urz79n/SBonwb8K228OZbMXhYDH+uJlx+AcD8K9BoAqavafb9KvbMnAuIHizj+8pHt615Z46ukfx98HfEEiny5J7i33g8Brm2AUY9yPXsa9erwz4iwPpPgT4dsNzW+g+KrOGSTAysEMksAJ4A5AQccc0Ae50UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8+/tGagbj4X3ljpRSW88SeIFskgDLukaFxGcevz2yDJ6bgM17/NIkMLyysqRopZmYgAAckknpXgfxDiTW/i38G9EV2SSDzNXmRgFOVVZFLYGMloXH1JoA920uyj07TLSxg4htoUhTj+FVAH6CrNFFABXjHxgtbi++EPxL007IlsbsTwOi4LJ+4uyTz13vIueOnSvZ64TxXYpqz+N9BRikuo6EpU7Vb5nW4iLAFhkjanBwOnPJwAdnpt3Hf6da3kP+quIkmTnPDAEfzqxXEfBDUItT+EXhGeH7qabDbn/AHol8tv1Q129ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXinLaBeQgLuuVFqu7oDKwjBPqAWBxXk2hW82vftV+I7+eKNrTw3pMFlA46q8yiQfo84/KvWNZRbjUNItmVZF+0md0YZG1EYhvwkMZHvj615R+zcf7X1T4i+LBNJNFq2uPFA7dGhi3GMg56BZcf8B6mgD22iiigArEvEC+MtMk8oYksbmNnx1IeEqp9eN+Px9626wvElwLXUvDshj3K+oeSzjqgeCUD8C2wfiD2oA4L9mNmtvhtNocpJm0HVLzTZMqVO5ZC54P8A10r1qvHvgyx074nfFbQnlUhNUj1JEyMn7QpdiB14wgP1HSvYaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8/8eatHpVr4t8QRXKrc6Ho0kMBJIWOeRTIVORgltttjr1HrVf8AZz0h9F+C/hiCZVEs8DXZI7iZ2kX/AMdZR+Fef/tBXd7dfBq3ghhX+0PFWtRqkMZyZY2Zmgzz18uK3B6817/pdlDpmmWljbAiC1hSCME5IVVCj9BQBZooooAK5/x3cR2XhyS8nLCC1uLa5lK/wok8bMeo4CgnnjiugrL8U6f/AGt4Y1fTef8ATLOa34/20K/1oA8b0Rhpf7YHiFJZSBq+iI8aHgFlEI/HiJzxnvXvFfNPxE1B7X9oL4S+KY0/c6taRWquoyrGQspx9Bcr+lfS1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFV9QvrTTbOS71G6gtLWIAyTTyCNEGccseByRXPj4heDWcqvivQWIyWK38TBMAk7iGwvAPXHQ+hoA6iiobK7t760hurG4iubWZBJFNC4dHU8hlYcEH1FTUAFYPjO7aDR1s4JvJvNTmWwt2GdwaTO5l90QSSfRDW9XgP7QnxUk8HX9hNoklpdXtrK0EUMqF0ExAMrkjGGSMogGeftL90oA4H4qeMF8QftKeDNAs/s66X4c1e0tYWjOd0pliMo6cYKrHjnBQnPPH15X5ieGdSvLPxfpOqQJPeX8N9FcoiktJNIJAwA4JLEj0PJ71+lei6vZ6xa+dZu4ZdolglQxzQMVDBZI2wyNhgcEA4IPQigDQooooAKKKiuriGztZrm7mjgt4UMkssrBURQMlmJ4AAGSTQB8v/ALQFnJonwp8DataSMdR8Nau2n20u3hVjaRQSPrbR19O6bewajp1rfWj77a5iWaJsfeRgCD+RFeXeMvCE/iL4CaxpX2J47+4jn1O3thHmRJWna5SMDnDHOwjPcjNV/wBlXxRH4h+Eun2j3DS3+kM1lOHI3BASYsAfw7Cqgnuh9KAPYaKKKACiiigAooooAKKKKACiiigAooooAKKKKACuf8V+Ik0VYoIBA97KrS/v5RHFbwIMyXEzH7saDGT3JUcZJG5czxW1vLPcOscMSF3djgKoGST+FfL/AMQ9R1L4i/ESx+HlgtzbNeyx3viCVHO63gUbktiQCoEcbAkHKmaTseoBop45n8da3LH4D8Hnxpd2hVjrmuARWVs4fIMMLYCY3AjBWUhRu37d1ehafJ8Zo3ie9tfh9Jbry8EMt3E5A/hDEMoPvgivQfD+jad4e0a00nRbSKz061Ty4YIxwo6nk8kkkkk5JJJJJJrQoA8aSx8PXGqRW2v+Hb34feJLthFBqGl3IhhupHdtqJcxYSWQ+WD5cyBvm4U8mlvNR+LvhDUnjXSbTxzo37yUXCSRWd0g3EJGcYDEKFJ2xcliM8V65qFjaalZS2eo2sF3aTDbJBPGJEcejKeCPrXM6Kl74X1VNKvLq4vtEu3I0+6uJDLNbSYJ+zSNjLLgMUkYk8bGO7YXAMC68Y+LLnTLie78MT+F9OSJfN1C5nS6uEYnBWG3jDBmzgBpCqjIYhgCp+WfiVp9x4mmuL5bSG0e2UxhJ53T7JtZ3KNNMVD+Zv37mHmSSu5GBwfu+5giureW3uYklglQxyRuoZXUjBBB6givn7XfC8F549uPC+jGwu9aZDNmSMS22kWhPE0yHHmTYYJHBypHzvkEYAPnLwLJc6X4K1bVNBvLuDxDNqNvp0RsZfLuEheG4dsEHIVnjiyQAcRkZ5Ir1HS/EviTQpfCthYmyvbWx8PN4nvpPOeK8mjdJJZIpbgbmBLHcoAAO5N2etfQ1t8KPCCu0+oaZ/a186COS81CQzSMuCMD+FFwSNiKq44AA4qe9+GHhG7eR20poXltfsEjW11NAXttoXyW2OMx7VUbTwABgUAeJ2/7Rl1oun6Xfaxpmp3KajKJmhk8lkitS0igxSoELSDaMo6c8/MoIr6P8Q6l/ZPh3U9URFl+x2styELbQ+xC2M4OAcdcGvNta+BmgalDbWZurkaYiwQyW8oEjeRC8jxxxycMn+tKljuYqAAQea9Q1Wxi1TS7ywuS4guoXgkMbbWCspU4PY4PWgCiltrxiQS6npwfneY7BxxjjGZTgg9zn6Vl3uj3NvBFLqMt94jMKtII52jjjEgGQTFGgDjPTIdlIBUE81zdz4J+Itw8Qb4qPHGnBEWgQKzjkEsd3XBxwAMgHGRU1p8M9WG43/xI8YzPn5TBNDEAPcGNs0AaU2tXB12G4driFYgWeyaUfcCfMSAAFXkMHbK52gvGSUPHf8Kz13wZ461Hxd8NLuymtNSYyX2g3TtFFMPvfupBuAfcWKkgBd5H3ciusvPCXiCxsrVtL8U3+rmzfzfsesxW7i5ARhsE0caSROSRiXLFSBwRkHb8Km3vLKDUdImnis53cSWksYAiZSytHsHEbo4KkDjKtkEndQBjaJ4h8d6lcLFe+BbXR0xl57rW45VH+6sSMWPsdv1FVPH2vWugWH/FW+PodALRllTTbeNJ5AWAyEkEzsBgjKqOp/DM+JPxKtrTxfbeCNIF7ea3cR7pLaw+WV2YfJD5oP7gEEu8vVIwSvzEMuz4D+FuheGby51i6s7S+8SXtw13cXzxbhFIxJ2wBiTGg3EDB3EY3E4GADz97zRNZJgGh/FvxEsrh49T8y4t4XJ4DIplhjUdekYAzSXU0uktbLv8V+HvsQSIXOrSNbRmPadpe4iMto7Z+X9+oJ3D5tw+b6BpGUMpVgCpGCDyCKAPH/DPxQutHgsbPx7BfRgSmzudYuLMWqwTZAT7RGrMsYfPEisUIKn5Q3HsNeW+PPBdvpmi3M+hLbWWmiGRJ7WSMtbwIykMfLHHkH/lpEMAf61Nrqwkxv2c/GVxdJqfgfXLea01jQPlSGdi7+UMBk3ZO4RudqtnmNoupySAe10UUUAFFFFABRRRQAUUUUAcn8S7+Cx8Of6bC81i8hkugq7h5EKPcSKy/wASusJjI7+ZzxxXk37J+g/aG8S+Nb6RrnUtTnWAzyAbg21ZZ8Y4wZXx/wBshXa/tAXRtvBOohZoojLYyQsZCcLHJcW0TudvzYCSNkA85x3p/wCzXbNafBTw5E8bRH/SH2N1Aa4lIz+BFAHptFFFABWZ4n0w6xoN7Yxssc8keYJW/wCWUyndHJ9VcKw91FadFAHNat4vsNM+Hsvi6Y7rBLAX6qpwZAyBlUE92JAHua4/9nTRbu38EyeJNbYS674onOqXUpQA7G/1SAj+EL8wHbzCBXlnxq1ebUfh58PvBGii5I164WNHmZlxGkgSJGPCtyy8ZO3YCRypH1Ha28Npaw21tGsUEKCOONBgIoGAAPQAUAS0UUUAFFFFABRRRQAVzOkzf2TrfiaC6kgj0+Py9TRxlfKSRWEgbPH34ZHyP7/TjJ6avNPjFM1jZ38zCRLW98P6pZyzRRh2Eqw+bFwSOiJcEDuT1FAHm37KdvdeLPFPjP4i60m+8u7j7JbuZCwjz88iAHkBV8hVPZQRX0pXhv7IMC23w21KJEnRRqjMPOTYx3W1u24D+6d2VPdSDXuVABRRRQAhAYEMAQeCD3r5n8UWUngL47eEtftr7zYr+7GjXsMkh+6VjjSQ544ia23Hj5kB6NX0zXzx+1mLaDw1JKC8E4ubVxNAuGV3WfDsQRnJt4h3ICg4OBgA+h6KqaReDUNKsrwLtFxAk2303KD/AFq3QAUUUUAFFFFABRRRQB5n+0DLMnw61aOLyZI5LdVaCQbt2bm3XdjqdoZvbJGQavfAV4n+D3hbyCDGtoEBH8WGIJ9skZx2q98VdJvNb8G6npunWkdzPe2lzafMB8m+F9hznj96sQzzjrwBkc5+zj4sh8V/D95FkWS8tryYXbBQgeaU+e7KvZd0rAZA+6aAPU6KKKACq+pXaWGnXV5Lny7eJ5WwMnCgk/yqxXL+ObtDDb6YzSLHPuurt43VdlpDh5d2f4XOyIjriUnsSADyCz0CC8+PngPSI9jf8In4eWS8ic7lVwuxMcfe3SI2Sc8Z7ZP0PXjf7PiT6/deKPHd4Fxq92baxCxhUFvEzEsnfDSO+c85TJ617JQAUUUUAFFFFABRRRQAVzHxE0hdY0AQsyoFlCsxBO2OVWglPHcRTSEe4FdPVfUrOHUdOurG6Vmt7mJ4ZArFSVYEHBHI4PUUAeEfsqtPpU/i/wAMXFm1gLKW1uhbyEE+bJDsmKnJ3JuhG05PBGeSa9/r5l0bXX8H/HTRrfUo7m3h1UyW7kwZRZrhysqB+u03NurJwflkY5A4r6aoAKKKKACvnr9r4rH4KuXVSXeWyjfOcFc3JXv2OT/+vFfQteIfGGKPxLr2ieHrm2WUaprtrBFGshAntbVWluXfjDBTK6bc9RntigD2LQ7ZrLRdPtXJZ4LeOIkjqVUD+lXaKKACiiigAooooAKKKKAGTI0kLojmNipCuACVPY4PHFeE+GrK58B+JJ7nSbKzhtpJzBeWauEV4QzyyIhCgedAZGkiVsGW1kAAJjyvvNYHiTQpdQb7ZpVylnqix+UzSRebDcxZJ8mePI3pycEEMpZtpwzqwBqaVqVnq+nw32mXMV1aSglJYm3KcEgj6gggjqCCDyKt15XcazY+Hr+5v/FGla14Xu3kaWW805WvLG4JO3cWiQ7jtA5njRhuwvCjGPqXxg0GwkH2X4jaPcQOcpG+iTXU5yOBuhkRQeD1TuM0AewavqdppFhJeX8vlwpgDALM7E4VEUcs7EgKoBLEgAEnFeB+J9U1Hxrrl54P0ee1XxDq7bdWubcrKNHso3bEDkblMihjkBv9dIcMoUVgR6v41+J2qww+CbDV7OBwxfxTrq+W0CFNrC1RB5cJOXXMe6Rgy7mABNe5fCj4daP8N/Di6bpS+ddy4e9vnUCS5kA6n+6oydqZwAT1JZiAdRoul2WiaTZ6ZpcC29jaRLDDEpJ2oowBk8n6kknqau0UUAFFFFABRRRQAUUUUAFFFFAHjXx08BR6/wCTdwW3n3bMxtd8/lJHcsgjK7jkK0irHsZsKskMYyDKTXR/CLxrL4h01tK12RR4k04bJ2C7VvYxgC5j4AwcruUYKMdrKuQD3l7aw3tpNa3Kl4ZkKOAxU4PoRyD7jkV4V43+FTRak+sW2r6ro+pI/nLrWlwvL5jAMoa5gjIbzdjsPNQ7Wy5dVyAwB73RXjPhPxb8R7b7VYajpWieK5LdSYr/AEzUoIBMADgyKWypJ7hABWr/AMLMe0WMeK30Hw/JKCgtLbUm1O+8wnaqiCKIe5yC3bIGTgA77XdWj0y3IUxPeOjNFHI+xcKMl3bB2RrxucjjIHJKg+W/C3SF1z4han4siujeaHpkB0jSLkjIu5C2+7uQf4gZS6hlJU5bHAFDaH4j+IvmQ3FtqPhXwrcqpvJbuQDVtUX/AJ4sqnFvD80mV6+igOa9c0ywtdL062sNPgS3s7aNYYYkGFRFGAB+AoAs0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZmr+H9G1og6xpGnX5ClQbq2SXAPUfMDxU+l6Xp+k25g0qxtbKDOfLtoVjXP0UAVcooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rochester-Ochsner forceps have a large tooth and horizontal serration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_57_8095=[""].join("\n");
var outline_f7_57_8095=null;
